



(19) Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 406 557 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**17.10.2001 Bulletin 2001/42**

(51) Int Cl.7: **C12N 15/49, C12P 21/02,**  
**A61K 39/21, A61K 48/00**

(21) Application number: **90109892.1**

(22) Date of filing: **23.05.1990**

### (54) Multivalent repressor of gene function

Polyvalenter Repressor von Gen-Funktionen

Répresseur multivalent de gènes

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(30) Priority: **25.05.1989 US 356878**  
**07.07.1989 GB 8915602**  
**30.10.1989 GB 8924396**  
**29.11.1989 US 442670**

(43) Date of publication of application:  
**09.01.1991 Bulletin 1991/02**

(73) Proprietors:  
• Novartis AG  
4056 Basel (CH)  
• DUKE UNIVERSITY  
Durham North Carolina 27706 (US)

(72) Inventors:  
• Bachmayer, Helmut,  
A-2344 Maria Enzersdorf, (AT)  
• Boehlein, Ernst,  
A-2531 Gaaden, (AT)  
• Cullen, Bryan R.,  
Durham, North Carolina 27707, (US)  
• Greene, Warner C.,  
Chapel Hill, North Carolina 27514, (US)  
• Hauber, Joachim,  
A-2344 Maria Enzersdorf, (AT)

(56) References cited:  
**EP-A- 0 246 882**

• BIOLOGICAL ABSTRACTS DATABANK abstract  
no. 90027777; B. MERMER et al.: "Identification  
of a Trans-Dominant HIV-1 REV Protein Mutants  
by Direct Transfer of Bacterially Produced  
Proteins into Human Cells" & Nucleic Acid  
research 1990, vol. 18, no. 8, pages 2037-2044

- CELL vol. 58, no. 1, 14 July 1989, pages 205-214, Cambridge, MA, US; M.H. MALIM et al.: "Functional Dissection of HIV-1 Rev Trans-Activator-Derivation of a Trans-Dominant Repressor of Rev Function"
- CHEMICAL ABSTRACTS vol. 111, no.25, 18 December 1989, page 164, abstract no. 226165a, Columbus, Ohio, US; L. RIMSKY et al.: "Transdominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator" & Nature (london) 1989, vol.341, no. 6241, pages 453-456
- BIOCHEM. BIOPHYS. RES. COMMUN. vol. 162, no. 3, 15 August 1989, pages 963-970, New York, US; S. KUBOTA et al.: "Functional Similarity of HIV-I rev and HTLV-I rex proteins : Identification of a new Nucleolar-Targeting Signal in rev Protein"
- JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES vol. 2, no.3, 1989, pages 256-263; A. PERKINS et al.: "Structural and Functional Characterization of the Human Immunodeficiency Virus rev Protein"
- BIOTECHNOLOGY vol. 6, no. 7, July 1988, pages 794-799, New York, US; B.M. PETERLIN et al.: "Replication of the Human Immunodeficiency Virus: Strategies for Inhibition"
- CHEMICAL ABSTRACTS vol. 108, no. 19, 9 May 1988, page 160, abstract no. 162332k, Columbus, Ohio, US; M.R. SADAIE et al.: "Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1" & science (Washington, D.C., 1883) 1988, vol. 239, no. 4842, pages 910-913
- NATURE vol. 335, 20 October 1988, pages 738-740, London, GB; L. RIMSKY et al.: "Functional replacement of the HIV-1 rev Protein by the HTLV-1 rex Protein"

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 406 557 B1

- SCIENCE VOL. 235, 6 FEBRUARY 1987, PAGES 674-677, WASHINGTON D.C., US; W. WACHSMAN et al.: "HTLV x Gene Mutants Exhibit Novel Transcriptional Regulatory Phenotypes"
- CHEMICAL ABSTRACTS vol. 110, no. 7, 13 February 1989, page 163, abstract no. 52087t, Columbus, Ohio, US; A.D. FRIEDMAN et al.: "Expression of a truncated viral transactivator selectively impedes lytic infection by its cognate virus" & Nature (London) 1988, vol. 335, no. 6189, pages 452-454 (see also pages 395,396)
- PROC. NATL. ACAD. SCI. vol. 86, November 1989, pages 8222-8226, Washington, US; M.H. MALIM et al.: "Functional comparison of the Rev transactivators encoded by different primate immunodeficiency virus species"

**Description****1. FIELD**

5 [0001] The invention concerns the field of viral gene expression, more particularly the phenotypic expression of the rex (regulator of virion-protein expression) gene of HTLV-I and its equivalents in other retroviral species, such as rev of HIV-1.

**2. BACKGROUND**

10 [0002] Viruses, particularly human retroviruses like the human immunodeficiency virus type 1 (HIV-1) or the human leukemia virus type I (HTLV-I) are the causative agents for very serious diseases. This is in the case of HIV-1 the Acquired Immune Deficiency Syndrome (AIDS) and in the case of HTLV-I Adult T-cell Leukemia (ATL) as well as noncancerous conditions known as Tropical Spastic Paraparesis. HTLV-II is etiologically related to some cases of variant 15 T-cell hairy cell leukemia. Both virus groups are dividing their replication cycle, similarly to the DNA viruses, in an "early" and a "late" stage of gene expression. The "early" phase of gene expression is characterized by the expression of the regulatory proteins, while in the "late" phase the structural proteins are synthesized.

20 [0003] The HTLV-I genome is coding for an activator of viral transcription termed Tax. The equivalent of Tax in HIV-1 is termed Tat. Tax and Tat appear to act primarily on the retroviral LTR (long terminal repeat) for viral gene expression. In addition, HTLV-I encodes an activator of viral structural gene expression termed Rex. A functional Rex protein is responsible for the increased transport of unspliced viral mRNA out of the nucleus into the cytoplasm of the infected 25 cell. There these mRNA species are constituting the viral genome and encoding the structural proteins. Human Immunodeficiency Virus Type 1 (HIV-1) encodes a homologous protein termed Rev. The rev gene product is, as Rex in the HTLV-I system, absolutely required for the expression of the HIV-1 structural proteins.

30 [0004] The underlying reason for this is that the product of the rev gene (and its equivalents in other viral species) is having a dramatic effect on the selection of the splicing mode for the viral mRNA transcripts in infected cells. This effect is achieved in the case of Rev and Rex by posttranscriptional regulation, namely by enhancement of the transport into the cytoplasm of full-length mRNA transcripts, whereby expression of viral structural proteins such as Gag and Env for HIV-1 is initiated and expression of regulatory proteins is concomitantly suppressed (see e.g. for Rex M. Hidaka et al., EMBO J. 7 [1988] 519) or modulated (see e.g. for Rev M.H. Malim et al., Nature 335 [1988] 181). Thus Rev is not required for the expression of the fully spliced HIV-1 mRNAs encoding the viral regulatory proteins, including Tat and Rev.

35 [0005] In HIV-1 the selectivity of the induction noted above is due to an RNA target sequence required for Rev function termed Rev Response Element (RRE). RRE coincides with a large, 234 nucleotide RNA secondary structure present within the HIV-1 env gene. The equivalent structure in HTLV-I is termed Rex Response Element (RexRE or RRX). Rev appears to be the first protein which has been shown to regulate the nuclear export of RNA in a sequence specific manner.

40 [0006] Taking Rex as an illustration, the complete function of the Rex protein in regulating expression of the HTLV-I gag and env genes requires at least three functionally distinct component activities: nuclear and nucleolar localization, i.e. the capacity to be transported from the cytoplasmic site of synthesis of all proteins to the nucleus and there to be concentrated in the nucleolar region; specific recognition (directly or indirectly) of the RexRE (RRX) sequence in viral RNAs; and Rex effector activity, the presently still unknown activity of this regulatory protein which actually mediates export from the nucleus to the cytoplasm of partially spliced viral mRNA species that include the RexRE sequence.

45 [0007] Regarding the structural locations in the Rex protein where these component activities of the complete Rex function reside (i.e. the functional domains), all that was known prior to the present invention is that a positively charged peptide domain in the first twenty amino acids at the amino terminus of Rex is required for nucleolar localization (H. Siomi et al., Cell 55 [1988] 197-209).

50 [0008] As mentioned above both the rex gene product for HTLV-I and the rev gene product for HIV-1 are required for replication of the virus (see e.g. for HIV E. Terwilliger et al., J. Virol. 62, [1988] 655). The crucial importance of Rex and Rev is underscored by the fact that in spite of their different primary structures, they are related functionally, and HTLV-I Rex is able to exert its function in the other viral species, i.e. in HIV-1 (L. Rimsky et al., Nature 335 [1988] 738); thus even though

- Rev and Rex do not share any significant homology on the nucleotide as well as on the amino acid level,
- the nucleotide sequences and stem and loop structures of the RRE differ from those of the RexRE (RRX) in HTLV-I,
- computer-generated prediction of secondary structures of the Rex and Rev proteins reveal no significant similarities and
- the Rex protein does not appear to bind to the same part of the RRE as the Rev protein does,

it is nevertheless possible to substitute the Rev protein by the Rex protein in the HIV-1 system, and further, it has very recently been found that HTLV-I Rex and HIV-1 Rev can substitute for HIV-2 Rev (Rev2) and that HTLV-I Rex can also substitute for the analogous HTLV-II regulatory protein. This complementation is sufficient to rescue e.g. a rev-deficient HIV-1 provirus providing functional Rex protein in trans. On the other hand the reverse substitution to rescue a rex-deficient HTLV-I provirus by functional Rev protein does not seem to be feasible. Thus there is no complete symmetry in this respect. The basis for this lack of reciprocity is not yet understood, but it probably relates to differences in the functional aspects of these proteins that are required for target RNA sequence recognition.

**[0009]** Mutations in regulatory proteins may yield a gene product with a dominant negative phenotype over the wild-type function (I. Herskowitz, Nature 329 [1987] 317). Dominant negative mutant proteins, known as trans-dominant repressors, a small group of which have been discovered recently in several unrelated viruses, represent a novel class of anti-viral agents. In genetic analyses, negative mutations are those which cause a diminution or loss of a function of a gene. Dominant negative mutations are those that prevent other copies of the same gene, which have not been mutated (i.e. which have the wild type sequence), from functioning properly. On the other hand recessive negative mutations do not so inhibit wild-type counterparts. Further, some dominant mutations inhibit wild-type genes only when the mutant and wild-type genes are located on the same chromosome (DNA or RNA molecule). In this case the inhibiting mutation is said to be "cis-acting". Alternatively, a dominant mutation may inhibit the corresponding wild-type gene even when located on a separate chromosome. This type is classified as a "trans-acting" dominant mutation or, more simply, as a transdominant mutation.

**[0010]** A few of these so-called transdominant genes have been described, concerning genes for eukaryotic or Herpes virus transcription factors (I.A. Hope and K. Struhl, Cell 46 [1986] 885; R. Gentz et al., Science 243 [1989] 1695; S.J. Triezenberg et al., Gen. & Devel. 2 [1988] 718; A.D. Friedman et al., Nature 335 [1988] 452). Thus, when over-expressed some deletion mutants of the Herpes simplex virus trans-activator VP16 inhibit VP16 function, thereby precluding replication of HSV-1 in normally permissive cells. As regards retroviruses, transdominant mutants have also been described, e.g. for the Tax protein of HTLV-II (W. Wachsman et al., Science 235 [1987] 674) and, after the priority date for the present invention, for the HIV-1 tat (M. Green et al., Cell 58 [1989] 215) and gag (D. Trono et al., Cell 59 [1989] 113) genes.

**[0011]** These differences in compositions and functions of these two regulatory proteins indicate that comparison of Rex structure with that of the Rev protein or its known mutants offers no guidance at all for selecting mutations that might produce trans-dominant repressors of the viral proteins.

**[0012]** A therapeutic application of the above concepts would involve the inhibition of production or overproduction of a deleterious gene product by manipulation of the gene to create dominant negative mutations whereby the resultant gene is encoding mutant regulatory proteins which when expressed disrupt the activity of the wild-type function (I. Herskowitz, Nature 329 [1987] 219). In the situation of viral, e.g. retroviral infections it thus appears highly desirable to provide corresponding transdominant repressors of virus function by the construction of similar inhibitors of essential regulatory genes, e.g. inhibitors of the rev or rex gene. This approach would provide the requisite tools for "intracellular immunization", an approach to the treatment of viral infections first proposed in 1988 (D. Baltimore, Nature 335 [1988] 395).

### 3. SUMMARY OF THE INVENTION

**[0013]** Engineered transdominant versions of the HTLV-I rex and, respectively, of the HIV-1 rev gene have now been made, the product of which blocks HTLV-I, HTLV-II or, respectively, HIV-1 replication. Furthermore, the product of some of these engineered transdominant versions of the rex or rev gene blocks both HTLV-I (and in some instances HTLV-II) and HIV-1 (and in some instances HIV-2 and SIV) replication.

**[0014]** This appears to be the first reported occurrence of the preparation of viral repressors acting in more than one viral species, i.e. of transdominant gene products repressing the phenotypic expression of functionally equivalent genes of more than one viral species.

**[0015]** The invention thus concerns genes coding for proteins which transdominantly repress the phenotypic expression of functionally equivalent genes of more than one viral species and thus block replication of more than one viral species, particularly the mutant genes in pcRexM2, pcRexM7 and pcRexM8; M6, M7 and M13; and pM10, disclosed hereunder.

**[0016]** It also concerns genes coding for proteins which transdominantly repress the phenotypic expression of the rex gene of HTLV-I and/or HTLV-II and genes coding for proteins which transdominantly repress the phenotypic expression of the rev gene of HIV-1 and/or HIV-2 and/or SIV, particularly the mutant genes in pcRexM2, pcRexM7, pcRexM8, pcRexM17 and pcRex13Δ15; pM10, pΔ9/14, pΔ10/14, pM21, pM22, pM27, pM28, pM29 and pM32; and M6, M7 and M13, disclosed hereunder.

**[0017]** It also concerns a process for the preparation of these genes comprising isolating the corresponding wildtype gene from an appropriate expression system, putting this gene into an appropriate cloning system, introducing the

desired mutation into the gene and recovering the resultant mutant gene from the clones having the desired mutation. It also concerns a process for the preparation of proteins as defined above which comprises expressing and amplifying a mutant gene as defined above in an appropriate expression and amplification system and recovering the expressed product therefrom.

5 [0018] It also concerns proteins which transdominantly repress the phenotypic expression of functionally equivalent genes of more than one viral species and thus block replication of more than one viral species, in particular the mutant proteins of pcRexM2, pcRexM7 and pcRexM8; M6, M7 and M13; and pM10, disclosed hereunder.

10 [0019] It also concerns proteins which transdominantly repress the phenotypic expression of the rex gene of HTLV-I and/or HTLV-II, and proteins which transdominantly repress the phenotypic expression of the rev gene of HIV-1 and/or HIV-2 and/or SIV, in particular the mutant proteins of pcRexM2, pcRexM7, pcRexM8, pcRexM17 and pcRex13Δ15; pM10, pΔ9/14, pΔ10/14, pM21, pM22, pM27, pM28, pM29 and pM32; and M6, M7 and M13, disclosed hereunder.

15 [0020] It also concerns a vector, e.g. a retroviral or plasmid vector containing a gene as defined above in a form suitable for achieving delivery in a functional state into a target mammalian cell in vivo or in vitro.

[0021] It also concerns a pharmaceutical composition containing a gene or protein as defined above in a form suitable for achieving the desired prophylactic or therapeutic effect, together with a pharmaceutically acceptable carrier or diluent, e.g. in the form of cells taken from a patient's body and treated in vitro prior to reinsertion.

[0022] It also concerns a method of treatment of viral infections comprising administering a gene or protein as defined above in a form suitable for achieving the desired prophylactic or therapeutic effect to a subject in need of such treatment, e.g. in the form of cells taken from a patient's body and treated in vitro prior to reinsertion.

20 [0023] Under "treatment" is to be understood the prophylactic as well as the curative treatment of viral infections, whereby "curative" includes the stabilization of a viral infection at a stage of latency.

[0024] It also concerns the genes, proteins and DNA segments defined herein for use as a pharmaceutical.

25 [0025] The invention also concerns inhibitors derived from the genes, proteins and DNA segments defined herein and able to mimic the transdominant, i.e. primarily the RNA-binding domain in a mutant Rex or Rev protein as defined above, such as low molecular weight inhibitors or neutralizing monoclonal antibodies. Low molecular weight means herein a molecular weight below about 10 kD, especially below about 1 kD.

[0026] Further aspects which the invention concerns are as listed hereunder:

- A trans-dominant repressor of HIV-1 Rev function comprising a first and a second domain, the first domain having substantially the specific binding functions of wild-type HIV-1 Rev and the second domain not having the activation functions of wild-type HIV-1 Rev, the second domain being modified from wild-type HIV-1 Rev by one or more mutations; preferably the first domain comprises from about amino acid position 10 to about amino acid position 68 of wild-type Rev and the modified second domain is derived from about amino acid position 68 to about amino acid position 90 of wild-type Rev; especially, the above one or more mutations are missense or deletion mutations which occur between about amino acid position 68 and about amino acid position 90, preferably from about 78 to about 86, especially from about 78 to about 83 or 84 of wild-type Rev, the specific binding functions of the first domain of wild-type HIV-1 Rev remaining substantially functionally intact; particularly the repressors pM10, pM21,

30 pM22; pM27, pM28, pM29 and pM32 disclosed hereunder;

- a trans-dominant repressor of HIV-1 Rev function comprising a first domain having substantially the specific binding functions of wild-type HIV-1 Rev, this transdominant repressor not having the activation functions of wild-type HIV-1 Rev; preferably the first domain comprises from about amino acid position 10 to about amino acid position 68 of wild-type Rev and the transdominant repressor lacks from about amino acid position 68 to at least about amino acid position 90 of wild-type Rev; particularly the repressors pΔ9/14 and pΔ10/14 disclosed hereunder;

- a DNA segment that encodes a trans-dominant repressor of the function of the HTLV-I Rex protein, the repressor being modified from a wild-type form of the Rex protein by at least one trans-dominant negative mutation in the peptide domain of the wild-type Rex protein that exhibits the effector activity of the Rex protein, this repressor having substantially the nucleolar localization activity of the wild-type form of the Rex protein; preferably such a DNA segment in which the peptide domain of the wild-type Rex protein comprises from about amino acid position 59 to about amino acid position 121, especially in any one of the following amino acid positions: 59, 60, 64, 65, 119, 120 and 121; particularly a DNA segment comprising any of the following mutant rex genes: M6, M7, M13 and variants and derivatives thereof which exhibit trans-dominant repression of HTLV-I Rex protein function;

- a corresponding trans-dominant repressor of the function of the HTLV-I Rex protein so modified from a wild-type form, preferably having the ability to repress either the function of the HIV-1 Rev protein or the function of the HTLV-II Rex protein;

- a method for identifying a specific inhibitor of the gene activation function of the Rex protein comprising the steps of:

5            i) providing a genetic system comprising:

- a DNA segment encoding an mRNA which comprises a regulatory response element that is recognized by the Rex protein, and at least one unused splice site (i.e. a region or intron that is bounded by splice recognition sequences but that has not been spliced out of the mRNA);
- a DNA segment encoding a rex gene that is capable of being expressed to produce a protein product which induces export of the mRNA from the nucleus;
- a host cell transformed by the DNA segment encoding the rex gene and by the DNA segment encoding the mRNA and having the capability to express the protein product of the rex gene and to express the mRNA;

10            ii) contacting a culture comprising the cells of this genetic system with an agent suspected of being a specific inhibitor of the Rex protein under conditions such that the agent enters the cells;

15            iii) determining the effect of this agent on export from the nucleus of the mRNA that comprises the unused splice site; and

20            iv) determining the effect of the agent on export from the nucleus of a spliced form of the mRNA in which the splice site has been used;

25            whereby a decrease in the export of the mRNA that comprises the unused splice site together with no decrease in the export of the spliced form of the mRNA indicates that the agent is a specific inhibitor of an activity of the HTLV-I rex gene or of an activity of a product of the rex gene; the mRNA regulatory element that is recognized by the Rex protein preferably being derived from an mRNA of a virus selected from HTLV-I, HTLV-II and HIV-1;

30            - an identification method as defined above wherein the decrease in the export of the mRNA that comprises the unused splice site is preferably detected by determining the level of production of a first protein, encoded by the mRNA that comprises the unused splice site, and the increase in export of the spliced form of the mRNA is preferably detected by determining the level of production of a second protein, encoded by the spliced form of the mRNA;

35            - an identification method as defined above wherein the mRNA comprising the regulatory response element and the splice site is encoded by a plasmid comprising the 3' end of an HTLV-I provirus including the coding regions for the Rex and Tax proteins, the complete env gene, the Rex response element and the entire 3' LTR; preferably by plasmid pgTAX-LTR disclosed hereunder; and the rex gene preferably is provided on plasmid pRex;

40            - plasmid pgTAX-LTR;

45            - a reagent kit for screening agents to identify a specific inhibitor of the gene activation function of the Rex protein according to the above identification method, comprising:

- a DNA segment encoding an mRNA which comprises a regulatory response element that is recognized by the Rex protein, and at least one unused splice site;
- a DNA segment encoding a rex gene that is capable of being expressed to produce a protein product which induces export of the mRNA from the nucleus; and
- a container containing a host cell transformed by the DNA segment encoding the rex gene and by the DNA segment encoding the mRNA, the cell having the capability to express the protein product of the rex gene and the mRNA;

50            - a method of inhibiting replication of HIV-1, HTLV-I or HTLV-II comprising introducing a DNA segment as defined above into a cell having the ability to replicate one of these viruses and to express the DNA segment to produce a transdominant repressor of HTLV-I Rex function; and

55            - a method of inhibiting HIV-1, HIV-2 and SIV, especially HIV-1 replication comprising introducing into a cell infected with HIV-1 a trans-dominant repressor of HIV-1 Rev function.

**4. EXPLANATION OF THE FIGURES****4.1. for 5.1. and 6.1.:**

5 [0027]

**Figure 1:** Nucleotide and amino acid sequence of HTLV-I *rex* [the amino acid positions substituted by oligonucleotides (1) (amino acid positions 87, 88, 89) and (2) (position 94) are marked, as well as positions 82, 90, 91 and 97. The full sequence contains 567 nucleotides, coding for 189 amino acids.

10

**Figure 1A:** Location of the 29 mutations introduced into the HTLV-I *rex* gene. The HTLV-I *rex* gene encodes a 189 amino acid protein. Using site-directed mutagenesis, missense substitutions were introduced at defined amino acid residues (indicated by boxes) and are named according to their location within the *rex* gene. The pΔ mutant is named for the extent of the deletion, i.e., 13Δ15 is deleted between the introduced mutation for M13 and M15.

15

**Figure 2A:** Rex immunoprecipitation:

SDS/polyacrylamide gel electrophoretic analysis of 7 of the 30 *rex* mutants after Rex immunoprecipitation (shows that pcRexM2, pcRexM7, pcRexM8, pcRexM13, pcRexM14, pcRexM17 and pcRex13Δ15 are still producing Rex protein):

20

A: pgtat (negative control for Rex antibody)

B: pcRex

C: pcRexM2

D: pcRexM7

25

E: pcRexM8

F: pcRexM13

G: pcRexM14

H: pcRexM17 (the lower molecular weight in this lane is possibly due to a change in the modification of this protein by, e.g., phosphorylation)

30

I: pcRex13Δ15

**Figure 2B:** Biological phenotype of the mutants:

As for Figure 2A, after Tat immunoprecipitation:

35

A: pgtat + pXF3

B: pgtat + pcRev

C: pgtat + pcRex

D: pgtat + pcRexM2

E: pgtat + pcRexM7

40

F: pgtat + pcRexM8

G: pgtat + pcRexM13

H: pgtat + pcRexM14

I: pgtat + pcRexM17

45

K: pgtat + pcRex13Δ15

**Figure 2C:** As for Figure 2B (shows that some of the Rex mutants are transdominant over wildtype Rex, namely pcRexM2, pcRexM7, pcRexM8, pcRexM14, pcRexM17 and pcRex13Δ15):

50

A: pgtat + pXF3 + pXF3

B: pgtat + pcRev + pXF3

C: pgtat + pcRex + pcRexM2

D: pgtat + pcRex + pcRexM7

E: pgtat + pcRex + pcRexM8

55

F: pgtat + pcRex + pcRexM13

G: pgtat + pcRex + pcRexM14

H: pgtat + pcRex + pcRexM17

I: pgtat + pcRex + pcRex13Δ15

**Figure 2D:** As for Figure 2B (shows that some of the Rex mutants are transdominant over wildtype Rev, namely pcRexM2, pcRexM7, pcRexM8 and pcRexM13 partially):

- 5 A: pgtat + pXF3 + pXF3
- B: pgtat + pcRev + pXF3
- C: pgtat + pcRev + pcRexM2
- D: pgtat + pcRev + pcRexM7
- E: pgtat + pcRev + pcRexM8
- F: pgtat + pcRev + pcRexM13
- 10 G: pgtat + pcRev + pcRexM14
- H: pgtat + pcRev + pcRexM17
- I: pgtat + pcRev + pcRex13Δ15

**Figure 3:** Rex mutants which have been constructed

**Figure 4:** Sequence of the 29 oligonucleotides synthesized to mutagenize the rex coding sequence.

#### 4.2. For 5.2. and 6.2.:

[0028]

**Figure 5:** Location of mutations introduced into the HIV-1 rev gene. The HIV-1 rev gene encodes a 116 amino acid protein with the predicted sequence shown. The border between the two coding exons of rev is indicated (SP). Clustered point (pM) mutations were introduced by oligonucleotide-directed mutagenesis, as indicated by the boxed residues. These mutations were named according to their location within Rev, with pM1 the most N-terminal and pM14 the most C-terminal. All introduced mutations affected from two to four adjacent amino acids and all (except pM7) introduced a unique BgIII site into the rev gene sequence. These introduced sites facilitated the subsequent construction of N- and C-terminal deletion (pΔ) mutants. The pΔ mutants are named for the extent of the deletion, e.g. pΔ11/14 is deleted between the introduced pM11 and pM14 mutations.

**Figure 5A:** Location of further missense and deletion mutations introduced into the HIV-1 rev gene (- = deleted amino acid).

**Figure 6:** DNA and corresponding amino acid sequence of pcREV.

**Figure 7:** DNA sequence corresponding to mutation sites M1-M14.

**Figure 8:** Immunoprecipitation of the HIV-1 rev and tat trans-activators.

**Figure 9:** HIV-1 proviral rescue assay.

**Figure 10:** Subcellular localization of Rev and selected Rev mutants by indirect immunofluorescence.

**Figures 11A and 11B:** Analysis of Rev mutants for a dominant negative phenotype.

**Figure 12:** Competitive inhibition of Rev function.

**Figure 12A:** Domain structure of the HIV-1 rev trans-activator. The 116 amino acid full-length protein is encoded by two exons separated by an intron largely corresponding to the viral env gene. The "binding" and "activation" domains are shown as hatched boxes encompassing residues 23-56 (approx.) and 78-83, respectively. S = splice junction; NL = highly basic region important for nuclear localization that shares considerable identity with the "Arg-rich" RNA binding motif.

4.3. For 5.3. and 6.3.:

[0029]

5 **Figure 13:**

(A) Amino acid sequence of the HTLV-I Rex protein and location of each of the 25 point mutations introduced. Nucleotides encoding each of the boxed amino acids were removed and replaced in-frame by an oligonucleotide encoding the aspartic acid-leucine dipeptide.

10 (B) Structure of the Rex-responsive pgTAX-LTR expression vector. The 3' end of the CR-1 HTLV-I provirus from the HindIII site at map position 5013 (M. Seiki et al., *Proc. Natl. Acad. Sci. USA* **80** [1983] 3618-3622) through the 3' LTR, was inserted into the pBC12/CMV expression vector. This fragment contains the two coding exons for Tax (white boxes), the complete env gene and the entire 3' LTR of HTLV-I including the RexRE (RRX) (S.M. Hanly et al., *Genes Develop.* **3** [1989] 1534-1544).

15

**Figure 14:**

20 (A) Rex, but not Rev or IL-2, activates the expression of HTLV-I Env protein by the pgTAX-LTR vector. Subconfluent cultures of COS cells were cotransfected with pgTAX-LTR and pREX (L. Rimsky et al., *Nature* [1988] 738), pREV (M.H. Malim et al., *Nature* **335** [1988] 181-183) or pCMV-IL-2 (B.R. Cullen, *Cell* **46** [1986] 973-982). In the final lane, cells were transfected with pREX in the absence of pgTAX-LTR. Env protein production was analyzed by immunoprecipitation and gel electrophoresis. The migration of known molecular weight standards is indicated on the left.

25 (B) Analysis of Rex function of rex mutants. After insertion into the pBC12/CMV expression vector, each of the 25 rex mutants (designated M1-M18 and M21-M27, see Fig. 13A; mutants designated M19 and M20 have not been constructed) was cotransfected with pgTAX-LTR, and the cultures were analyzed for Rex-dependent HTLV-I Env protein expression as described in Example 12.

30 **Figure 15:** Simultaneous analyses by immunoprecipitation of HTLV-I Env, Tax and Rex proteins in COS cells cotransfected with pgTAX-LTR and vectors for the inactive (M1, M2, M6, M7, M13) or impaired (M15) Rex mutants or the wild-type pREX, pREV and pCMV-IL-2 vectors. (A) Env production; (B) Tax production; (C) Wild-type and mutant Rex protein production.

35 **Figure 16:** Subcellular localization of HTLV-I Rex mutants by immunofluorescence. The wild type, M6, M7 and M13 Rex proteins are localized in the nucleoli and nuclei of expressing cells. In contrast, the M1 Rex protein is detected only in the cytoplasm while the M2 protein is distributed throughout the cell. The M15 mutant is localized in the nuclei of expressing cells but, in contrast to the wild-type Rex protein, appears to be excluded from the nucleoli.

40 **Figure 17:**

45 (A) Analysis of the ability of rex mutants to inhibit function of the wild-type Rex protein. Each culture was cotransfected with pgTAX-LTR, pREX and either one Rex mutant (Lanes 1-6), pREX (Lane 7), pREV (Lane 8) or pCMV-IL-2 (Lane 9). HTLV-I Env production was analyzed as in Fig. 14.

(B) The HTLV-I rex transdominant mutants inhibit the function of HIV-1 Rev protein. Cells were cotransfected with pgTAT, pREV and pBC/CMV-IL-2 or the M6, M7 and M13 transdominant Rex mutants and assayed for Rev-induced production of the truncated 72 amino acid form of the Tat protein (Lane 2). M6, M7 and M13 (Lanes 3-5) completely inhibited the HIV-1 Rev protein as only the full-length 86 amino acid form of the Tat protein was detected.

50 (C) The HTLV-I transdominant Rex mutants block Rex rescue of the replication of Rev-deficient HIV-1 provirus. Cells were cotransfected with a rev-deficient HIV-1 proviral plasmid and pREX in the presence of the indicated fold excess of the M1, M6, M7 and M13 mutants. Supernatant levels of HIV-1 p24 Gag protein were measured.

55 **5. DETAILED DESCRIPTION**

[0030] The procedures and techniques to be used in employing the present invention are known in the art.

[0031] Viral species is herewith to be understood as being a taxonomically distinct species such as HTLV-I, HTLV-II, SIV, HIV-1 and HIV-2. The invention concerns in particular the field of retroviruses, especially human retroviruses.

[0032] The genes the expression of which it is a goal of the invention to repress are preferably genes coding for an undesirable property, such as a function resulting in activation of the provirus and maturation into infective particles., e.g. rev of HIV-1 and HIV-2.

5 [0033] rev and Rev as used herein mean HIV-1 rev and HIV-1 Rev, respectively, unless specified otherwise. Thus the equivalent rev and Rev of other viral species, such as HIV-2, are specified as "HIV-2 rev (rev2)" and "HIV-2 Rev (Rev2)", respectively, etc.

10 [0034] Insofar as their preparation is not particularly described herein, the compounds, vectors, cell-lines, etc. used as starting materials or reagents are known and publicly available or may be obtained in conventional manner from known and publicly available materials, or equivalent materials may be prepared in conventional manner from known and publicly available materials. Thus e.g. the Rex gene may be recovered from any isolate of HTLV-I and the Rev gene from any isolate of HIV-I and pgTAX-LTR may be recovered e.g. from HUT102 or MT1. Alternatively, genes may be created by chemical synthesis according to the genetic code to produce a protein having the required amino acid sequence. A transdominant repressor of Rex or Rev function is made by standard recombinant DNA methods or by standard chemical methods for peptide synthesis, or by a combination of these methods, all of which are conventional.

15

### 5.1.

20 [0035] The invention in **one approach** concerns transdominant repressors of the Rex function in HTLV-I, especially transdominant repressors of the Rex function in HTLV-I which are also active on the functionally equivalent but structurally unrelated Rev function in HIV-1.

[0036] Specifically, modified rex coding sequences were constructed and expressed and found to possess the above property.

25 [0037] The wildtype rex coding sequence (see Figure 1) was changed using a purchasable mutagenesis system in accordance with "Oligonucleotide-directed in vitro mutagenesis system Version 2", Amersham, England (1988), Code RPN.1523, hereinafter shortened as "Amersham protocol". The construction of the final expression vectors was carried out in stages entailing in succession:

- 30 1) preparation of a bacteriophage M13 vector carrying the rex coding sequence,
- 2) mutagenesis of the rex coding sequence and
- 3) recloning of the mutated gene into mammalian expression plasmids.

[0038] 30 mutants were constructed, including one deletion mutant. The position and nature of the 29 site-directed mutations is indicated in Figure 3. The corresponding oligonucleotides used for mutagenesis are listed in Figure 4. They all carry a BgIII restriction site.

35 [0039] The rex coding sequence was isolated from plasmid pcRex (= pRex) (L. Rimsky et al., Nature 335 [1988] 738). Other sources for the wildtype rex gene are available. Thus the rex gene may be cloned e.g. in analogous manner to that described for the gag, pol, env and tax genes of HTLV-I in B.K. De and A. Srinivasan, Nucl. Ac. Res. 17 No. 5 (1989) 2142, out of the whole genome of established HTLV-I-infected cell lines such as HUT102 (TIB 162) and MT2 (J.G. Sodroski et al., Science 225 [1984] 381; I. Miyoshi et al., Nature 294 [1981] 770; V. Manzari et al., PNAS 80 [1983] 1574), using e.g. the polymerase chain reaction.

40 [0040] The tat and rev coding sequences were isolated from plasmids pgTat and pcRev (M.H. Malim et al., Nature 335 [1988] 181). They may alternatively be isolated e.g. from a HIV proviral clone such as λHBZ (Catalog No. 70, AIDS Research and Reference Reagent Program, June 1989, NIH).

45 [0041] The biological activity of the various rex genes obtained was tested in a sensitive assay for the action of the HIV-1 rev and the HTLV-I rex gene products by expression of the different genes in COS cells (Gluzman et al., Cell 23 [1981] 175. As well as initiating the synthesis of viral structural proteins, the Rev and the Rex proteins both induce the production of a truncated form of the HIV-1 Tat regulatory protein (M.H. Malim et al., Nature 335 [1988] 181-183; L. Rimsky et al., Nature 335 [1988] 738-740). Coexpression of a genomic HIV-1 tat gene together with a functional HIV-1 rev or a HTLV-I rex gene leads to the cytoplasmic expression of an unspliced tat mRNA encoding a truncated one-exon form of Tat that is 72 amino acids in length. The absence of a functional Rev or Rex protein will allow the expression of a full length Tat protein of 86 amino acids, corresponding to the two-exon form of Tat. Thus the presence of an active trans-repressor of the rev or rex function leads to reduced or abolished production of the 72 amino acids Tat protein. This difference can readily be visualized upon immunoprecipitation analysis.

50 [0042] As shown in Figure 2C, 6 out of 30 mutants were found, namely pcRexM2, pcRexM7, pcRexM8, pcRexM14, pcRexM17 and pcRex13Δ15, which had a trans-dominant Rex repressor. The same pattern also was found with pcRev (see Figure 2D), namely for pcRexM2, pcRexM7, pcRexM8 and partially pcRexM13, indicating that transdominance is not limited to the HTLV-I gene, and that some of the mutants are transdominant for both genes, namely, in this particular instance, pcRexM2, pcRexM7 and pcRexM8.

[0043] While some of the results first obtained indicated that the most successful mutations were located between amino acid position 87 and 94, and it thus appeared that a portion of the rex/rev gene lying between about amino acid position 82 and about position 97 was of particular significance in the engineering of trans-dominant Rex/Rev repressors, further testing has shown that the range for preferred positions of the mutations on the Rex protein is broader, i.e. that they may lie at least as near the N-terminus as amino acid position 22 and at least as far toward the C-terminus as amino acid position 101.

## 5.2.

[0044] In a further approach focussing on the Rev function in HIV-1, transdominant rev repressors have also been found. It is possible that some of these at least also inhibit the Rex function in HTLV-I or HTLV-II, but this has not been tested here.

[0045] On the other hand it has been found that some of these at least also inhibit the Rev function in HIV-2 and SIV<sub>mac</sub>.

[0046] Extensive mutational analysis further has led to the delineation of at least two distinct functional domains within rev that appear to be essential for trans-activation. These domains are envisioned as comprising a "binding domain" which directs the Rev protein to its appropriate target substrate, and an "activation domain" which permits the functional consequences of the binding event, transcriptional activation, to be displayed.

[0047] Consequently, two functional domains within rev have been defined: a binding domain likely to direct the Rev protein to its cellular target, and an activation domain permitting the nuclear export of the incompletely spliced RNAs that encode the structural proteins Gag and Env. Mutation of the activation domain of Rev results in the expression of defective Rev protein which acts as transdominant inhibitor of Rev function. Such mutants markedly inhibit HIV-1 replication when expressed in transfected cells in culture and are thus also transdominant, as are the mutants obtained under 5.1.

[0048] Detailed information concerning this second approach is also apparent from 6.2. hereunder. The transdominant mutants found thereby are designated as pM10, pΔ9/14 and pΔ10/14 (see Examples 4 to 11) and pM21, pM22, pM27, pM28, pM29 and pM32 (see Examples 11a and 11b), whereby pM10 was found to be effective in inhibiting not only HIV-1 rev gene function but HIV-2 rev and SIV<sub>mac</sub> rev gene function as well.

[0049] Preferred under the above 9 transdominant mutants are pM10, pM21 and pM32, especially pM10.

## 30 5.3.

[0050] In a yet further approach focussing on the Rex function in HTLV-I similarly to 5.1., transdominant rex repressors have also been found and a method developed that permits detection of Rex activities and is useful for the identification of specific inhibitors of Rex function which do not interfere generally with other viral or host cell functions. This Rex inhibitor detection method utilizes a genetic system comprising a Rex-responsive "reporter" gene that encodes an unspliced form of an mRNA that includes a regulatory element, a RexRE (RRX) for instance. In this system, a protein providing Rex function induces the export of this unspliced mRNA from the cell nucleus to the cytoplasm. In the absence of Rex function, this mRNA is spliced before export to the cytoplasm, as indicated above. Upon contacting cells comprising this genetic system with an agent suspected of being an inhibitor of Rex function, specific inhibition of HTLV-I Rex function by that agent is indicated by a decrease in nuclear export of the unspliced form of this particular mRNA, together with no decrease in nuclear export of the spliced form of this same mRNA. This method is useful for detecting, for example, chemical inhibitors of the HTLV-I Rex protein, e.g. inhibitors able to mimic the transdominant domain in a mutant Rex or Rev protein, e.g. low molecular weight chemical inhibitors, as well as transdominant mutant forms of Rex that act as repressors of Rex.

[0051] To identify transdominant negative mutations of the rex gene, again a series of point mutations were produced, that altered segments of two or three amino acids at various sites throughout the linear sequence of the Rex protein, and several transdominant repressors of HTLV-I Rex protein function identified among these mutants, several of which additionally transdominantly repressed the HTLV-II Rex and/or the HIV-1 Rev protein function and are thus, analogously to some of the mutants found under 5.1., also repressing the phenotypic expression of functionally equivalent genes of more than one viral species.

[0052] Accordingly, the invention also relates to a method for identifying a specific inhibitor of the gene activation function of the Rex protein, comprising the several steps defined under 3. above. As noted above the HTLV-I Rex protein is able to replace the function of the HIV-1 Rev protein. In addition it has now been found that Rex also can substitute for the analogous HTLV-II regulatory protein. Thus mRNAs from at least any of these three viruses, which have a response element that is recognized by Rex and at least one appropriate unused splice site, can be used in this method.

[0053] Preferably the mRNA comprising the response element and the splice site is encoded by a plasmid comprising

the 3' end of an HTLV-I provirus including the coding regions for the Rex and Tax proteins, the complete env gene, the Rex response element RexRE (RRX) and the entire 3' LTR. An example of such a plasmid is pgTAX-LTR. For convenience in mutant analyses that require controlling the ratio of copies of a mutant rex gene to wild-type rex gene copies, the rex gene on pgTAX-LTR is inactivated by a recessive negative mutation and in this system, the active rex gene is provided on the separate plasmid designated pREX. However, for testing chemicals, for instance, the active rex gene could be provided on the same plasmid or other vector DNA as the required mRNA of this system. Further, this active rex gene might comprise a natural sequence variant isolated from a strain of HTLV-I other than that used in the present invention, or any other mutant form of rex gene that is capable of being expressed to produce a protein product which provides the gene activation function of the Rex protein, including induction of export of the above mRNA from the nucleus.

[0054] The elements of the genetic system listed above could also be provided by using a DNA segment encoding the entire functional genome of a retrovirus as a part of this genetic system; it can be applied to infected cells. However, for safety reasons as well as convenience, this genetic system preferably is unable to produce any infectious virus. This is accomplished by design into the system of a genetic defect that prevents expression of at least one viral activity which is essential for production of any infectious virus from which some genetic element is used. For example, this may be done by omitting from the system at least a part of one viral gene or by some other mutation.

[0055] Preferably the host cell transformed by the rex gene and by the DNA segment encoding the mRNA is exemplified by COS cells which have been transfected by the plasmid vectors described above. Thus the term "transformation" as used herein encompasses the term "transfection" and indicates a genetic transformation involving a vector DNA that encodes an infectious agent, particularly a virus. After transfection such a vector can then spread from the minority of transformed cells in the culture to the majority of other cells by means of infectious virus particles, thereby providing a larger sample of host cells expressing the genes of interest. In addition the transformation of the host cells in the present genetic system need not result in stable constructs; either stable or transient gene expression systems may be used to provide the required mRNA and rex gene. Thus a wide variety of known expression systems may be employed in identifying inhibitors according to the present method.

[0056] In this method a decrease in the export of the mRNA that comprises the unused splice site together with no decrease in the export of the spliced form of this mRNA indicates that the agent is a specific inhibitor of an activity of the HTLV-I rex gene or of an activity of a product of the rex gene. For the case of a chemical agent that is found to be a specific inhibitor by use of the present method, the mode of action, in principle, could include specific inhibition of transcription or translation of the mRNA. More likely modes of action, however, include specific inhibition of one or more activities of the Rex protein, including nucleolar localization, recognition of the Rex response element, or the Rex effector function.

[0057] Advantageously, the decrease in the nuclear export of the mRNA that comprises the unused splice site is detected by determining the level of production of a first protein, this first protein being encoded by the mRNA that comprises the unused splice site (i.e., only the unspliced form of the mRNA encodes this first protein); and the increase in the nuclear export of the spliced form of the mRNA is detected by determining the level of production of a second protein, this second protein being encoded by the spliced form of this mRNA.

[0058] Preferably the mRNA, in the unspliced form, encodes the HTLV-I Env protein. Splicing of this mRNA results in a shorter mRNA that encodes another HTLV-I protein, Tax. In e.g. Examples 12 and 13 below, the nuclear export of the unspliced mRNA having an RexRE (RRX) element is detected by expression of the Env protein. Further, inhibition of such export of the unspliced mRNA, which results from inhibition of Rex function, is detected by a decrease in production of the Env protein. However, since this decrease might also result from some general toxicity of an agent to the virus or the host cell, specific inhibition of rex gene function is indicated by a decrease in Env expression together with no decrease in export of the spliced form of the mRNA, as reflected in no decrease in production of the HTLV-I Tax protein. Thus preferably simultaneous analysis of HTLV-I Env, Tax and Rex protein expression is effected.

[0059] In e.g. Examples 12 and 13 below the expression of the Env and Tax proteins is determined by immunoprecipitation with appropriate antibodies and electrophoretic analysis of the resulting precipitates. Alternatives for, e.g., large scale screening of samples for specific inhibition of Rex function include for instance enzyme-linked immunoassay (ELISA) methods for Env and Tax, or alteration of the mRNA by genetic engineering to provide some other, more convenient products for indicating expression of the spliced and nonspliced forms. For example, the mRNA could be altered to encode an enzyme that can be detected by addition of a colorless substrate which produces a color upon hydrolysis, such as E. coli  $\beta$ -galactosidase. If the gene for this enzyme is inserted in place of the env gene, the unspliced mRNA form would produce this enzyme while the spliced form would not. A second similarly convenient indicator gene could also be encoded in the mRNA so that it would be expressed in the spliced mRNA form, for example, by fusion to the Tax sequences. Further variations on the above approaches for rapid and efficient mass screening would be readily apparent to the man of the art.

[0060] In another aspect the invention relates to a reagent kit for screening agents to identify a specific inhibitor of the gene activation function of the Rex protein according to the method above, comprising the components listed under

3. above. This kit optionally further comprises any of the following: media that are used in the culturing of cells; reagents that are used in determining the level of nuclear export of either the spliced or the unspliced form of the reporter mRNA, either directly by nucleic acid hybridization, for example, or indirectly by immunological detection, for instance, of the protein products of the spliced and unspliced forms of this mRNA; and instructions for use of any of the above components of this kit for practising the method of the invention.

5 [0061] The above method has been used for screening various rex gene mutants for dominant negative mutations. When these rex gene mutants were coexpressed with the plasmid pgTAX-LTR in the Rex inhibitor detection system of the invention, a class of mutations was found, similarly as under 5.1., comprising amino acid substitutions in the Rex protein at position 59-60, 64-65 and 119-121, which resulted in proteins that not only lacked Rex function but also 10 acted as transdominant repressors of the function of the wild-type Rex protein and which also acted as transdominant repressors of the function of the wild-type Rev protein.

10 [0062] This mutational analysis also produced a second class of negative mutants comprising substitutions at Rex amino acid positions 5-7 and 14-15 which lacked Rex function. These mutant proteins were neither appropriately targeted to the cell nucleus nor transdominant. Further, a third class of negative mutants, exemplified by a single mutant 15 which has substitutions at Rex amino acid positions 141-143, retains partial Rex function and was targeted to the nucleus but failed to localize in the nucleolar region of the nucleus; this mutant protein was also not a transdominant repressor of HTLV-I Rex function. These results raise the possibility that the nucleolar localization activity may involve sequences other than the positively charged residues identified at the amino terminus (H. Siomi et al. Cell 55 [1988] 197-209). In addition, the findings suggest that for a Rex protein mutant to serve as a transdominant repressor of Rex 20 function, that mutant may need to have not only a nuclear targeting activity but also a distinct nucleolar localization activity of the Rex protein.

25 [0063] These findings on the Rex mutants here also define approximate bounds of at least two functionally distinct peptide domains within the Rex protein, a first one involved in nuclear and nucleolar targeting and a second involved in effector activity. The Rex mutants deficient in nuclear targeting are located in the positively charged peptide domain at the amino terminus of Rex that has been previously shown to function as a nucleolar localization signal; when a peptide comprising the amino terminal twenty amino acids was attached to another protein by recombinant DNA means, this domain induced both nuclear targeting and nucleolar localization of that protein in a pattern similar to that observed for Rex (H. Siomi et al. [1988] supra). Thus it is not likely that the mutant at Rex amino acid positions 141-143 lies in a region that is required for nucleolar localization, even though this mutant was targeted to the nucleus but failed 30 to localize in the nucleolar region of the nucleus. Rather, the alteration in this mutant most likely affects the Rex nucleolar localization function in the amino terminal domain indirectly, for instance, through interference with proper protein folding.

35 [0064] The second major functionally distinct domain of Rex encompasses amino acids 59-60 (tyrosine-isoleucine), 64-65 (tyrosine-tryptophan) and 119-121 (threonine-phenylalanine-histidine). An alteration at each of these discrete sites (M6, M7 and M13 mutants) leads to the production of a Rex protein that both lacks biological activity and displays transdominant inhibitory properties. Five different mutations having no effect on Rex function separate the region of M6 and M7 from that of M13 in the linear sequence of the Rex protein, indicating that the interaction of these two discrete regions within this functional domain may require proper protein folding. Thus the entire linear portion of the Rex protein encompassing these two regions of amino acids that are most critical for Rex effector function appears to 40 contribute to the effector function of the Rex protein and, therefore, represents the domain to be mutated to produce transdominant repressors of Rex.

45 [0065] The present findings do not address the domain of Rex in which is located the activity required for recognition of the RexRE (RRX) in an mRNA. Accordingly, it is not known whether to serve as a transdominant repressor of Rex function a mutant rex protein must retain the ability to bind (directly or indirectly) to the RexRE, or to the recognition element of some other virus that is recognized by Rex.

50 [0066] Another aspect of the invention relates to a DNA segment that encodes a transdominant repressor of the function of the HTLV-I Rex protein as well as such a transdominant repressor. This repressor is a protein that is modified from a wild-type form of the Rex protein by at least one mutation that negatively affects the effector activity of the Rex protein. This repressor also has substantially the nucleolar localization activity of the wild-type form of the Rex protein. In particular, the negative mutation of this repressor is one that affects an amino acid in the peptide domain of the wild-type Rex protein that comprises from about amino acid position 59 to about amino acid position 121, more particularly in any of the following positions: 59, 60, 64, 65, 119, 120 and 121. The DNA segment encoding the Rex repressor is exemplified by any of the following mutant rex genes: M6, M7, M13 and variants and derivatives thereof which exhibit transdominant repression of HTLV-I Rev protein function.

55 [0067] The sequence of this DNA segment is derived from the Rex gene of any isolate of HTLV-I (L. Rimsky et al., Nature 335 [1988] 738-740; M. Seiki et al., Science 227 [1985] 1227-1229) or is created by chemical synthesis. The transdominant repressor of Rex function is made by standard recombinant DNA methods or by standard chemical methods for peptide synthesis or by a combination of these methods, all of which are well-known in the art of genetic

engineering.

[0068] The mutations that negatively affect the effector activity of the Rex protein are exemplified as described herein. However other types of mutations designed to produce localized effects on the protein structure at or close to these same amino acid positions also are highly likely to produce variants and derivatives of Rex which exhibit transdominant repression of HTLV-I Rex protein function according to the present invention. Such localized defects include, for example, deletions or insertions of single amino acids or substitutions of chemically or structurally similar amino acids. On the other hand, more extensive deletions or insertions, or substitutions that disrupt secondary structure (e.g., a proline in a  $\beta$ -sheet region) are highly likely to have effects on distant parts of the protein through influence on protein folding; therefore, such mutations at the indicated positions within the domain required for Rex effector function are not likely to produce mutant Rex proteins that retain substantially the nucleolar localization activity of the wild-type form of the Rex protein.

[0069] The transdominant Rex mutants of 5.3. above were also tested for Inhibition of Rev function and found to be repressors of HIV-1 Rev as well. The anti-viral potential of this class of transdominant Rex mutants has been demonstrated using an assay for inhibition of HIV-1 replication.

[0070] In addition and as already mentioned above it has now been discovered that HTLV-I Rex can also functionally substitute for the analogous HTLV-II regulatory protein, even though the nucleotide sequence of the corresponding response element in HTLV-II has a somewhat different stem and loop structure from that of the RexRE (RRX) in HTLV-I.

[0071] The invention thus further relates to a method of inhibiting replication of HIV-1, HTLV-I and HTLV-II comprising introducing a DNA segment as defined above which encodes a transdominant repressor of Rex function into a cell having the ability to replicate one of these viruses. This cell also has the ability to express the DNA segment to produce the transdominant repressor. This cell may be one that was previously infected by one or more of these viruses or this cell may be an uninfected target cell for one or more of these viruses.

[0072] For the preferred embodiment of the genetic system mentioned above a Rex responsive reporter plasmid, pgTAX-LTR was prepared (Fig. 13B). Briefly, the pgTAX-LTR vector contains the two protein coding exons of the tax gene separated by the HTLV-I env gene and a complete HTLV-I 3' LTR containing the RexRE (RRE). Expression of these HTLV-I sequences is promoted by the immediate early region of the human cytomegalovirus and additional polyadenylation sequences are provided by the 3' region of the rat preproinsulin gene (B.R. Cullen, Cell 46 [1986] 973-982). This vector produces Env only in the presence of Rex, however Tax is synthesized in the presence or absence of Rex. This vector does not itself produce Rex due to the introduction of a mutation at the SphI site which is coincident with the Rex translation initiation codon. In the absence of Rex, pgTAX-LTR produces Tax protein reflecting translation of the spliced mRNA species from this vector that lacks virtually all of the env sequences. However, when pgTAX-LTR is cotransfected with the rex expression plasmid pREX, synthesis of the HTLV-I Env protein is activated. This 62-68 kD protein is readily identified as evidenced by immunoprecipitation with the anti-HTLV-I envelope monoclonal antibody 0.5 alpha (S. Matsushita et al., Proc. Natl. Acad. Sci. USA 83 [1986] 2672-2676) (Fig. 14A, Lane 1). In contrast, no HTLV-I Env protein is detected when pREX is replaced by either pREV (Lane 2) or pCMV-IL-2 (Lane 3), which encode respectively the HIV-1 Rev protein and human IL-2 polypeptide. Similarly, no Env protein is identified when cells are transfected with pREX in the absence of pgTAX-LTR (Lane 4).

[0073] Thus in the genetic system defined above HTLV-I Env expression by pgTAX-LTR is specifically induced in the presence of a protein having the gene activation function of the wild-type Rex protein. In the system including a gene that provides a protein having Rex function, if contact with an agent inhibits Rex function, Tax protein continues to be produced unless that agent affects some viral or cellular activity that is not related to the expression of the gene or the product of the gene that provides Rex function, i.e. unless the agent is not a specific inhibitor of that gene or its product. Thus, as indicated in Example 12 and Figure 15, advantageously the exemplary method for identifying specific inhibitors of Rex function includes the simultaneous analysis of HTLV-I Env, Tax and Rex protein expression.

[0074] It may be noted that in the case of specific inhibition of Rex function by transdominant repressors described below and in Figure 15 the production of HTLV-I Tax protein evidently increases. This is probably a result of an increase in the nuclear export of the spliced form of the Env mRNA that is not exported prior to splicing due to a lack of Rex function. However, in principle a specific inhibitor of Rex function may prevent splicing of the mRNA but not induce export of the unspliced RNA. Accordingly, the present method for identifying specific inhibitors of Rex function requires only that there be no decrease in the nuclear export of the spliced mRNA that, in the present situation, produces the Tax protein.

[0075] The use of this system is exemplified in Example 12 below. In this mutational analysis again oligonucleotide-directed mutagenesis, in the M13 bacteriophage, was employed to alter the primary sequence of the rex gene, at 25 discrete sites (Fig. 13A). The boxed amino acids were replaced by the dipeptide aspartic acid-leucine by insertion of an in-frame oligonucleotide duplex which also contained the diagnostic BglII restriction site. Each of these rex mutants was then inserted into the pBC12/CMV eucaryotic expression vector (B.R. Cullen, Cell 46 [1986] 973-982) and the mutations were verified by DNA sequencing.

[0076] Each of the rex mutations was examined for biological activity by cotransfection with the pgTAX-LTR vector.

While nineteen of these rex mutants displayed a wild-type phenotype, five mutants (M1, M2, M6, M7 and M13) lacked apparent env gene activation activity and one mutant (M15) displayed only partial function (Fig. 14B). COS cells were next cotransfected with these six rex defective mutants and the pgTAX-LTR vector, followed by simultaneous analysis of HTLV-I Env, Tax and Rex protein expression as described in Example 12 (see also Fig. 15 A-C). While HTLV-I Env was only detected in the presence of the wild-type Rex protein (Fig. 15A, Lane 7) or the partially active M15 mutant (Fig. 15A, Lane 6), the 40 kD Tax protein was detected in all of the cultures (Fig. 15B). Thus the lack of env gene expression observed with the M1, M2, M6, M7 and M13 mutants is due to the specific loss of Rex biological activity rather than non-specific, toxic effects of these proteins in the transfected COS cultures. Each of the mutant Rex proteins was also identified in these cultures indicating that all of the mutants were expressed in a stable manner (Fig. 15C). The M2, M6 and M13 mutants migrated in a manner that was indistinguishable from the wild-type Rex protein (Fig. 15C, Lanes 2, 3, 5 and 7), whereas the M7 and M15 proteins exhibited a smaller apparent molecular weight (Lanes 4 and 6) and the M1 mutant yielded an electrophoretic doublet of proteins (Lane 1). Sequencing of the protein coding regions in the M1, M7 and M15 mutants failed to reveal any changes other than the specific mutations introduced. Thus the biochemical basis for these apparent differences in size likely reflects altered post-translational processing of these mutant Rex proteins.

[0077] Like the wild-type Rex protein, *in situ* immunofluorescent staining of cells transfected with the biologically inactive M6, M7 or M13 Rex mutants, as detailed in Example 12, revealed normal targeting to the nucleoli and nuclei of expressing cells (Fig. 16). In sharp contrast the M1 mutant protein was detectable only in the cytoplasmic compartment, while the M2 Rex mutant was distributed in an approximately homogeneous manner throughout the cell. Consistent with these findings is the fact that the M1 and M2 mutations altered basic amino acid residues located within the positively charged peptide domain that functions as a nucleolar localization signal. The partially active M15 mutation lead to a pattern of nuclear localization of mutant Rex protein, but unlike the wild-type Rex protein the M15 protein did not localize further within the nucleolar region of the nucleus and, in fact, M15 appeared to be excluded from the nucleoli (Fig. 16). These results suggest that residues away from the basic amino acids at the N-terminus may be involved in or contribute to the nucleolar localization of Rex.

[0078] The rex mutants were also examined for their capacity to block the biological action of the wild-type HTLV-I Rex protein and the wild-type HIV-1 Rev protein (Fig. 17). When cotransfected with pgTAX-LTR and pREX in COS cells (Panel A), a 10fold molar excess of the M6, M7 and M13 mutants displayed a dominant negative phenotype in that the action of the wild-type Rex protein was markedly inhibited (Lanes 3-5). In contrast, the M1, M2 and M15 proteins acted as recessive negative mutants since the action of the wild-type protein was not altered (Lanes 1, 2, 6). Similarly, the Rev protein of HIV-1 did not interfere with the action of the Rex protein (Lane 8) nor did IL-2 (Lane 9).

[0079] The capacity of the trans-dominant Rex mutants to block the function of Rev in the HIV-1 system was examined next (Fig. 17B). When cotransfected with pgTAT and pREV in COS cells, a 10-fold molar excess of M6, M7 or H13 Rex mutants inhibited the action of the Rev protein (Lanes 3, 4, 5) as evidenced by diminished expression of the 72 amino acid form of the Tat protein. The ability of these transdominant Rex mutants to block HIV-1 viral replication was also studied (Fig. 17C). Replication of a Rev-deficient HIV-1 provirus, pHXB2-Bam-p3 (L. Rimsky et al., *Nature* 335 [1988] 738) in the presence of Rex and graded amounts of transdominant Rex mutants was studied by transfection of COS cells with these plasmids. As indicated by synthesized levels of the HIV-1 p24 Gag protein in culture supernatants, the transdominant Rex mutants (M6, M7 and M13) produced dose-related inhibition of HIV-1 replication. In contrast, the recessive negative M1 mutant of Rex was without significant effect on HIV-1 replication.

[0080] Together, these findings with the various rex mutants of Examples 12 and 13 hereunder indicate the approximate boundaries within the Rex protein of at least two different structural domains having different activities. Thus one domain is defined by the M1 and M2 mutations, is located at the N-terminus, involves amino acids 5-7 and 14-15 and appears to play a role in targeting of the protein to the nucleus and thence to the nucleolus. This positively charged domain may also be involved in Rex binding either directly to the RexRE (RRX) or to other proteins that directly contact this RNA element. The second domain, which has been described above, is critical for the Rex effector function and, therefore, can be mutated to produce transdominant repressors.

#### 5.4.

[0081] Summarizing the findings under 5.1., 5.2. and 5.3. above, it is concluded that:

- a) a generally applicable principle has been found for producing viral inhibitors by mutating a critical regulatory protein, such as Rex or Rev;
- b) this principle appears applicable to the production of mutant regulatory proteins acting on a plurality of viral species; and

c) the specific transdominant mutants which have been constructed and identified are:

- HTLV-I Rex mutants effective in inhibiting HTLV-I rex gene function:
  - pcRexM2, pcRexM7, pcRexM8, pcRexM17 and pcRex13Δ15  
(see 5.1. and Examples 1-3);
  - H6, M7 and M13 (see 5.3. and Examples 12-13);
- HIV-1 Rev mutants effective in inhibiting HIV-1 rev gene function:
  - pM10, pΔ9/14 and pΔ10/14 (see 5.2. and Examples 4-11);
  - pM21, pM22, pM27, pM28, pM29 and pM32  
(see 5.2. and Examples 11a and 11b);
- HTLV-I Rex mutants effective in inhibiting HTLV-I rex gene function and also effective in inhibiting HIV-1 rev gene function:
  - pcRexM2, pcRexM7 and pcRexM8 (see 5.1. and Example 3);
  - M6, M7 and M13 (see 5.3. and Examples 12-13);
- HTLV-I Rex mutants effective in inhibiting HTLV-I and HTLV-II rex and HIV-1 rev gene function:
  - M6, M7 and M13 (see 5.3. and Examples 12-13);
- HIV-1 Rev mutant effective in inhibiting HIV-1 rev gene function and also effective in inhibiting HIV-2 rev and SIV<sub>mac</sub> rev gene function:
  - pM10 (see 5.2. and Example 11b).

30 6. EXAMPLES

[0082] The following Examples illustrate the invention. They are not to be viewed as being limitative.

## 35 6.1.

Example 1: Construction of a transdominant HTLV-I rex gene**1. Cloning of the rex coding sequence into the RF-DNA of bacteriophage M13**

40 [0083] 5 µg pcRex DNA were treated with 10 units each of restriction enzymes HindIII and EcoRI in 20 µl restriction enzyme incubation buffer (10 mM Tris-HCl pH 7.5; 10 mM MgCl<sub>2</sub>; 50 mM NaCl; 1 mM Dithiothreitol) at 37°C for 3 hours. The reaction mixture was directly loaded onto a 1 % agarose gel (Seakem FMC Inc., Rockland, ME, USA) containing 1 µg/ml ethidium bromide and subjected to electrophoresis at 50 V; 25 mA for 4 hours in Tris-acetate buffer (T. Maniatis et al., Molecular Cloning, A Laboratory Manual [1982], Cold Spring Harbor Laboratory, New York, p. 156). The separated DNA was visualized on a 366 nm UV-lamp and an appropriate gel slice containing the 1.5 kb rex fragment was excised. This gel section was placed in a dialysis bag containing 500 µl Tris-borate buffer (Maniatis, p. 156). The DNA was electroeluted into the buffer and precipitated at -20°C with ethanol.

45 [0084] 5 µg of bacteriophage M13mp10 RF-DNA were treated with the restriction enzymes HindIII and EcoRI and the 7.2 kb vector M13 fragment was isolated from a 1 % agarose gel in the same way.

50 [0085] 200 ng phage DNA and 1 µg cRex DNA were mixed in 20 µl ligation buffer (50 mM Tris-HCl pH 7.4; 10 mM MgCl<sub>2</sub>; 10 mM Dithiothreitol; 1 mM ATP) with 1 unit of T4-DNA-ligase and incubated for 15 hours at 16°C. This reaction mixture was used directly to transform and plate out E. coli strain TG1 (Amersham protocol, p. 16-18).

55 [0086] The DNA of appropriate phage plaques was checked by endonuclease cleavage with the restriction enzymes HindIII and EcoRI, followed by analytical gel electrophoresis through a 1 % agarose gel containing 10 µg/ml ethidium bromide in Tris-acetate buffer. A bacteriophage carrying the rex coding sequence was identified and designated mp10rex.

[0087] Single-stranded mp10rex DNA was isolated using a large scale preparation protocol (Amersham protocol p. 24-25).

2. Mutagenesis of the rex coding sequence in mp10rex

[0088] As a prerequisite of the mutagenesis it was necessary to synthesize appropriate single-stranded DNA molecules. 29 oligonucleotides (see Figure 4) were made, which eventually led to 30 mutants, of which the following seven oligonucleotides led directly or (see Example 2) indirectly to the mutants which were found to be successful in terms of transdominant phenotype:

10 (1) 5' - TG GAC AGA GTC TTA GAT CTG GAT ACC CAG TCT -3'  
BgIII

15 (2) 5' - AC TAT GTT CGG CCA GAT CTC ATC GTC ACG CCC -3'  
BgIII

20 (3) 5' - CC TAC ATC GTC ACA GAT CTC TGG CCA CCT GTC -3'  
BgIII

25 (4) 5' - TCG GCT CAG CTC TTA GAT CTC TTA TCC CTC GA -3'  
BgIII

30 (5) 5' - AG CTC TAC AGT TCA GAT CTC CTC GAC TCC CCT -3'  
BgIII

35 (6) 5' - GT TCC TTA TCC CTA GAT CTC CCT CCT TCC CCA -3'  
BgIII

40 (7) 5' - CT CCT TCC CCA CCA GAT CTA CCT CTA AGA CCC -3'  
BgIII

50 Oligonucleotide (1) is substituting the amino acid residues phenylalanine (position 30), phenylalanine (position 31) and serine (position 32) in the Rex protein by the amino acids leucine (position 30), aspartic acid (position 31) and leucine (position 32).

55 Oligonucleotide (2) is substituting the amino acid residues alanine (position 58) and tyrosine (position 59) in the Rex protein by the amino acids aspartic acid (position 58) and leucine (position 59).

Oligonucleotide (3) is substituting the amino acid residues proline (position 63) and tyrosine (position 64) in the Rex protein by the amino acids aspartic acid (position 63) and leucine (position 64).

Oligonucleotide (4) is substituting the amino acid residues tyrosine (position 87), serine (position 88) and serine

(position 89) in the Rex protein by the amino acids leucine (position 87), aspartic acid (position 88) and leucine (position 89).

Oligonucleotide (5) is substituting the amino acid residues leucine (position 90) and serine (position 91) by the amino acids aspartic acid (position 90) and leucine (position 91).

5 Oligonucleotide (6) is substituting the amino acid residue serine (position 94) by the amino acid leucine.

Oligonucleotide (7) is substituting the amino acid residues arginine (position 100) and glutamic acid (position 101) in the Rex protein by the amino acids aspartic acid (position 100) and leucine (position 101).

**[0089]** All oligonucleotides are introducing BgIII restriction sites in frame of the rex coding sequence.

10 **[0090]** The oligonucleotides have been synthesized on solid support on an Applied Biosystems 380A synthesizer using β-cyano-ethylphosphoamidite chemistry. Purification was done by 8 % polyacrylamide gel electrophoresis, followed by elution of the main product and ethanol precipitation. Phosphorylation of the oligonucleotides using ATP and polynucleotide kinase was carried out as described in the Amersham protocol, p. 13. The oligonucleotide-directed mutagenesis reaction was effected according to the Amersham protocol, p. 13-16. This was followed by transformation and plating out of E. coli strain TG1 as described on pages 16-18. The DNA of different plaques was screened by restriction endonuclease analysis using the enzymes BgIII and EcoRI.

15 **[0091]** From all seven mutations one clone was identified carrying the introduced mutation in the rex coding sequence. These clones have been designated mp10rexM2, mp10rexM7, mp10rexM8, mp10rexM13, mp10rexM14,

20 **[0092]** mp10rexM16 and mp10rexM17. A further clone, mp10rexM15, was used in the construction of the deletion mutant (see Example 2).

### 3. Recloning of the mutated rex genes into mammalian expression plasmids

**[0092]** The mutated rex genes were moved back from the bacteriophage M13 vectors into the original expression plasmid. 5 µg pcRex DNA were incubated with 10 units HindIII and 10 units EcoRI restriction endonuclease at 37°C for 3 hours. The reaction mixture was loaded directly onto a 1 % agarose gel containing 10 µg/ml ethidium bromide and subjected to electrophoresis in Tris-acetate buffer at 50 V; 25 mA for 4 hours. The HindIII-EcoRI vector fragment was electroeluted out of the appropriate gel slice and precipitated with ethanol.

**[0093]** 5 µg of the mutants obtained under 2. were treated in the same way and fragments containing the rex coding sequence were isolated.

**[0094]** 200 ng of the isolated vector fragment and 1 µg of the isolated rex sequences were mixed together separately in 20 µl of ligation buffer in the presence of 1 unit of T4-DNA-ligase and incubated at 16°C for 15 hours. The resultant reaction mixtures were directly used to transform E. coli strain HB101. The DNAs of different bacterial colonies were analysed using the restriction endonucleases HindIII, Asp718 and BgIII, followed by analytical gel electrophoresis through a 1 % agarose gel. Plasmids identified in this way carrying the rex genes were designated pcRexM2, pcRexM7, pcRexM8, pcRexM13, pcRexM14, pcRexM15, pcRexM16 and pcRexM17, respectively.

#### Example 2: Construction of a deletion mutation in the rex coding sequence

**[0095]** 5 µg of pcRexM13 DNA were treated with 10 units each of the restriction enzymes BgIII and EcoRI. The larger DNA fragment, containing the vector backbone and the 5' portion of the rex coding sequence was isolated as described above. In parallel 5 µg of pcRexM15 DNA treated in analogous manner and the smaller DNA fragment, containing the 3' portion of the rex coding sequence was isolated.

**[0096]** 200 ng of the isolated pcRexM13 DNA fragment were mixed with 1 µg of the isolated pcRexM15 DNA fragment and incubated in 20 µl of ligation buffer in the presence of 1 unit of T4-DNA ligase at 16°C for 15 hours. This manipulation led to a rex coding sequence where amino acid positions 87, 88 and 89 are identical with those in clone pcRexM13 and position 90-94 are deleted.

**[0097]** The reaction mixture was then directly used to transform E. coli strain HB101. The DNA of different clones was screened by restriction endonuclease digestion employing the enzymes HindIII, Asp718 and BgIII. A positive clone was identified and designated pcRex13Δ15.

#### Example 3: Biological activity

##### a) Biological activity of the mutant genes in mammalian cells

**[0098]** 0.25 µg of the rex wildtype and each mutant rex gene expression vector was mixed with 0.25 µg of the genomic tat (trans-activator) expression vector pgtat (M.H. Malim et al., Nature 335 [1988] 181) and transfected into the Cos cell line as described in B.R. Cullen, Meth. Enzymol. 152 (1987) 684-703. At 60 hours post-transfection cultures were

labeled for 3 hours with 300 µCi/ml of  $^{35}\text{S}$ -cysteine and analyzed for expression of the HIV-1 Tat and the HTLV-I Rex protein by immunoprecipitation analysis. A rabbit anti-peptide antibody directed against amino acid residues 1-61 of Tat and a rabbit anti-peptide antibody directed against amino acid residues 173-189 of Rex were used in this experiment as described in B.R. Cullen, *J. Virol.* **62** (1988) 2498-2501. Precipitated proteins were resolved on SDS/polyacrylamide gels and visualized by autoradiography.

**[0099]** The rex mutant genes encoded in the vectors pcRexM2, pcRexM7, pcRexM8, pcRexM14, pcRexM17 and pcRex13Δ15 yielded a negative phenotype for rex action in this assay system (see Figure 2B, Lanes D, E, F, H, I and K) whereas controls (Lanes B and C) and other mutants (Lane G) yielded a positive phenotype.

**[0100]** All of these phenotypically negative Rex mutant clones are able to produce a Rex-specific protein recognized by the polyclonal anti-Rex antibody described above (Figure 2A, Lanes C to E and G to I). In contrast, the mutation in clone pcRexM16 resulted in a protein undetectable by the Rex-specific antibody; this is believed to be due to a decreased protein half-life (not shown).

**b) Transdominant repression of wildtype HIV-1 rev and/or HTLV-I rex function by pcRexM2, pcRexM7, pcRexM8, pcRexM13, pcRexM14, pcRexM17 and pcRex13Δ15**

**[0101]** The same experimental set-up was used to examine the ability of the rex mutants to inhibit *in trans* the function of the wildtype Rev and Rex protein. 0.25 µg of the genomic tat expression vector pgtat, 0.25 µg of the wildtype rev (pcRev) or the wildtype rex (pcRex) expression plasmid and an excess of each rex mutant expression plasmid (5 µg) were mixed separately and transfected into Cos cells. The influence of the mutants on the wildtype Rev or Rex function was measured by Tat-specific immunoprecipitation as described above.

**[0102]** The result of this experiment shows that the six rex mutants pcRexM2, pcRexM7, pcRexM8, pcRexM14, pcRexM17 and pcRex13Δ15 have the ability to inhibit the wildtype rex-mediated trans-activation (see Figure 2C, Lanes C, D, E, G, H and I), that the four rex mutants pcRexM2, pcRexM7, pcRexM8 and (partially) pcRexM13 have the ability to inhibit the wildtype rev-mediated trans-activation (see Figure 2D, Lanes C, D, E and F), while some of the mutants, namely, in this instance, pcRexM2, pcRexM7 and pcRexH8, are able to inhibit both the wildtype rex- and the wildtype rev-mediated trans-activation.

**[0103]** This set of experiments demonstrates on the protein level the transdominant repression of Rev and/or Rex function by the above rex mutants.

**[0104]** The results from Examples 1 to 3 also seem to indicate the existence of two functional domains in the HTLV-I Rex protein. Towards the amino terminus there are two mutants (pcRexM7, amino acid positions 58,59 and pcRexM8, amino acid positions 63,64) that are transdominant over both Rev and Rex proteins. A second cluster, containing mutants transdominant only over the Rex protein, is located in the middle of the coding sequence. The additional rev/rex transdominant mutant (pcRexM2, amino acid positions 30-32) located between the nuclear localization signal and the cluster comprised of mutants 7 and 8 could be part of a third functional domain or alternatively the introduced amino acid change might disturb the tertiary structure of the protein, resulting in the observed transdominant phenotype.

## 6.2.

### **Example 4: Clustered point and deletion mutations in Rev**

**[0105]** The Rev protein is phosphorylated at serine *in vivo* and is localized predominantly to the cell nucleus where it is concentrated in the nucleoli. The mutational analysis described below addresses, among other factors, the relevance of these properties to the function of Rev as a trans-activator of HIV-1 structural gene expression.

**[0106]** Clustered point mutations (pM) were introduced into the HXB-3 strain of HIV-1 Rev by, again, oligonucleotide directed mutagenesis, as described by Taylor et al., *Nucleic Acids Res.* **13** (1985) 8765-8785. Specifically, a bacteriophage M13 mutagenesis system (Amersham Corp., Arlington Heights, IL, USA) was employed to introduce targeted nucleotide substitutions into full-length cDNA copies rev encoded by the expression vector pcREV (Malim et al., *Nature* **335** [1988] 181-183). The DNA and corresponding amino acid sequences of pcREV appear in Figure 6.

**[0107]** A series of clustered point mutations were introduced into Rev (see M1-M14, Fig. 5), cloned, and their sequences confirmed using a dideoxynucleotide sequencing system (Stratagene, La Jolla, CA, USA). The mutations were generally spaced evenly throughout Rev and served to target each of the 11 serine residues therein. The DNA sequence at and surrounding each mutation (pM1-pM14) are provided in Figure 7, with the altered nucleotides being underlined.

**[0108]** Most of the noted mutations resulted in codons for aspartic acid (Asp) and leucine (Leu) replacing the residues "boxed" in Figure 5. For ease of reference the mutations have been designated according to their location within Rev, e.g. pM1 being the most N-terminal mutation and pM14 the most C-terminal mutation.

**[0109]** While the precise structure of the various pM mutants is shown in Figure 7, the majority of mutations affected

only two codons. Exceptions to this generalization include M2, M4, M23, M24 and M25 which affected three codons and M6 which affected five codons. In most cases the amino acid substitutions arose from a two-amino acid missense mutation, however, in pM6, Asp and Leu replaced four arginine residues, thereby resulting in a two amino acid deletion, while pM4 contains an additional adjacent single amino acid substitution not observed in the parental REV, which involves the replacement of aspartic acid for tyrosine at position 23. These additional changes arose from single base errors in the single-stranded DNA oligonucleotide primer used in the mutagenesis protocol.

[0110] Most point mutations resulted in the formation of unique BgIII sites; pM7 was constructed by the simple deletion of two adjacent serine residues (see Fig. 5). The BgIII sites were all inserted in the same translational frame, thereby facilitating the subsequent construction of N-terminal and C-terminal deletion mutants ( $p\Delta$ ) of Rev. The  $p\Delta$  mutants are designated by the location of deletion, e.g.  $p\Delta 11/14$  has a deletion between the introduced pM11 and pM14 mutations.

#### **Example 5: Expression of Rev mutants**

[0111] The parental cytomegalovirus immediate early promoter based vector pBC12/CMV (B.R. Cullen, *Cell* 46 [1986] 973-982) was used as a negative control. Also employed herein were the genomic *tat* gene expression vector pgTAT, and the secreted alkaline phosphatase gene expression vector pBC12/RSV/SEAP (Malim et al., *supra*, and Berger et al., *gene* 66 [1988] 1-10, respectively).

[0112] The expression vector pcREV was modified to express the pM and  $p\Delta$  *rev* mutants described herein. Again, a qualitative assay involving the co-transfection into COS cells of the modified pcREV together with pgTAT was used to assay the expression of HIV-1 *rev* and *tat* in the mutants (Malim et al., *supra*, and Malim et al., *Nature* 338 [1989] 254-57). Specifically, COS cell cultures (35 mm) were co-transfected by DNA-mediated transfections as described by Cullen (*Meth. Enzymol.* 152 [1987] 684-703) using 0.25  $\mu$ g of pgTAT and 0.25  $\mu$ g of the wild-type or a modified pcREV expression vector with DEAE-dextran and chloroquine.

[0113] Sixty hours post-transfection, the cultures were labelled with [ $^{35}$ S]-cysteine and [ $^{32}$ P]-inorganic phosphate ( $[^{32}\text{P}]\text{-Pi}$ ) in parallel as described by Malim et al., 1988, *supra*, and Hauber et al., *J. Virol.* 62 [1988] 4801-04. The cells then were lysed with RIPA buffer and the relative level of *rev* and *tat* expression in the cultures assayed by immunoprecipitation analysis using rabbit polyclonal anti-peptide antisera (Malim et al., [1988], *supra*, and Cullen et al., *J. Virol.* 62 [1988] 2498-2501). More specifically, antisera to Rev amino acid residues 1-20 (REV1/20) was used for immunoprecipitation of the mutant proteins encoded by pM5 and pM6, while antisera to Rev amino acid residues 27-51 (REV27/51) was used for immunoprecipitation of all remaining mutant proteins. Immunoprecipitation analysis of *tat* expression was performed using rabbit polyclonal anti-peptide antisera to Tat amino acid residues 1-61 (TAT1/61).

[0114] The immunoprecipitated proteins were resolved by electrophoresis on 14 % discontinuous SDS-acrylamide gels and visualized by autoradiography. The results of these experiments are depicted in Figure 8, wherein the relative migration of known protein molecular weight markers is depicted to the right of the figure.

[0115] Immunoprecipitation of the [ $^{35}$ S]-cysteine and [ $^{32}$ P]-Pi labelled cultures with anti-Rev antisera are depicted in Figures 8A and 8C, respectively. Immunoprecipitation of the [ $^{35}$ S]-cysteine labelled cultures resulted in the majority of missense (pM) mutants yielding bands of an intensity and mobility comparable to the wild-type (Fig. 8A, lanes 1-14). Exceptions to this generalization include mutant pM6, which yielded an intense band of slightly faster mobility ( $M_r$  ~ 18 kD) and pM1, which yielded a faint band of significantly slower mobility.

[0116] Immunoprecipitation analysis of *tat* expression using anti-Tat antisera provided a qualitative assay for *rev* function using pgTAT as a model indicator. As indicated above, absent *rev*, pgTAT expresses a fully spliced cytoplasmic *tat* mRNA which encodes the 86 amino acid (aa) two exon form of *tat* protein exclusively. In the presence of *rev*, however, pgTAT induces the cytoplasmic expression of an unspliced *tat* mRNA that encodes a truncated, one exon form of the protein 72 aa long.

[0117] Wild-type *rev* migrates at a relative molecular mass ( $M_r$ ) of 19 kilodaltons (kD) and is readily detected in Figure 8 (lane 0), while the 86 aa and the 72 aa forms of *tat* migrate at 15.5 kD and 14 kD, respectively. Mock-transfected cultures yield no specific signal under these assay conditions (Malim et al., 1988, *supra*), while inspection of Figure 8B reveals that comparable levels of total *tat* protein were synthesized in both the cultures transfected with the mutant expression vectors and those co-transfected with the indicator construction pgTat. This suggests that none of the mutant Rev proteins were toxic to the transfected cells.

[0118] This analysis also demonstrates that 5 of the missense mutants and 2 of the deletion mutants of Rev were inactive (Lanes 4-7, 10, 16 and 20), while all other Rev mutants appeared fully able to induce 72 aa Tat expression. Four of the inactive missense mutations are clustered between amino acid residues 23 and 56 (M4 to M7), while the fifth inactive mutant (pM10) is separated by two fully functional mutants and affects residues 78 and 79. Deletion of either the 4 residues near the N-terminus ( $p\Delta 1/2$ ) or the 21 residues near the C-terminus of Rev ( $p\Delta 11/14$ ) had little or no effect on *rev* function. In contrast, deletion of additional sequences between residues 9 and 17 ( $p\Delta 1/3$ ) resulted in loss of *rev* function.

**Example 6: Trans-activation capacity of rev mutants**

[0119] In order to more rigorously evaluate the trans-activation capability of the rev mutants, their ability to rescue, in trans, a replication defective rev mutant of HIV-1 was tested. For purposes of this analysis, the rev HIV-1 provirus

5 of vector pHIV-1Δrev (designated pHXB2Bam-p3 by Feinberg et al., *Cell* 46 [1986] 807-17) was used, which contains a frame-shift mutation in the second coding exon of rev at amino acid 59 that renders the provirus incapable of replication, i.e., unable to produce a functional Rev protein when transfected into COS cells absent co-transfection with a vector capable of expressing HIV-1 rev in trans (Rimsky et al., *Nature* 335 [1989] 738-40). The ability of the mutants to rescue the rev provirus was analyzed as depicted in Figure 9, with viral replication being measured by quantitative

10 assay of the level of HIV-1 p24 Gag protein (pg/ml) released into the culture supernatant using an ELISA assay system for soluble p24 Gag expression (DuPont-NEN Inc., Billerica, MA, USA), with standards supplied by the manufacturer.

[0120] For purposes of control, transfection efficiency was monitored by co-transfection of the cultures with the Rev non-responsive vector pBC12/RSV/SEAP (12.5 ng/culture), a secreted alkaline phosphatase (SEAP) gene expression vector. Conveniently, SEAP levels were measured in parallel with supernatant p24 Gag levels. Additionally, some 15 cultures were also co-transfected with 125 ng of either the negative control vector pBC12/CMV (NEG) or a wild-type rev gene expression vector (pcREV).

[0121] COS cells cultures (35 mm) were co-transfected with 250 ng of pHIV-1Δrev and 125 ng of a control vector or one of the modified mutant-containing vectors. Supernatant media were sampled 65 hours after transfection and assayed for p24 Gag protein expression levels. SEAP levels were measured in parallel. The resulting values are recited 20 in Figure 9, with correction for the slight variability observed in supernatant SEAP levels (with mean SEAP activity set at 1.00 units, the observed standard deviation was ± 0.14 and the range 1.30 to 0.73).

[0122] Little variation in the supernatant level of SEAP activity was seen in this experiment, thus demonstrating equivalent transfection efficiency and confirming the lack of mutant induced cellular toxicity. Transfection of pHIV-1Δrev alone resulted in no detectable p24 Gag protein in the culture supernatant (Lane NEG), while co-transfection with a 25 wild-type rev gene expression vector effectively complemented the ability of pHIV-1ΔRev to induce the secretion of p24 Gag (Lane pcREV).

[0123] Additionally, all Rev mutants testing positive in the pgTAT based assay visualized in Figure 8B achieved a level of activity between 50 and 100 % of that noted for the wild-type rev construction in rescue assay, with the exception of M1, which achieved ~30 % activity, a reduction which may reflect the decreased *in vivo* stability of the M1 mutant.

30 All mutants that were scored as negative in Figure 8B were fully negative in the rescue assay (i.e., ≤ 10 pg/ml of p24 Gag), with the exception of M7 which yielded a barely detectable level of supernatant p24 Gag protein.

**Example 7: Rev phosphorylation not required for biological activity**

35 [0124] The HIV-1 Rev protein is phosphorylated at one or more serine residues when expressed *in vivo*. The mutations delineated in Figure 5 affect each of the 11 serine residues within the rev coding sequence. Thus, the immunoprecipitated [<sup>32</sup>P]-Pi labelled Rev proteins transiently expressed in transfected COS cell cultures were monitored in order to identify the *in vivo* phosphorylation sites of the HIV-1 rev (Fig. 8C). A comparison of the level of [<sup>32</sup>P]-Pi incorporation into rev with the level of [<sup>35</sup>S]-cysteine incorporated in a culture transfected in parallel (Fig. 8A) was used 40 to assess the effect of individual mutations on the level of phosphate incorporation. The results of this comparison are depicted in Table 1:

Table 1

Phenotypic analysis of HIV-1 rev gene mutants				
Clone	Rev <sup>a</sup> function	Phosphorylation <sup>b</sup>	Sub-cellular <sup>c</sup> localization	Trans-dominant <sup>d</sup> repression
wild-type	++	++	N	
M1	+	++	?	
M2	++	+	N	
M3	++	++	N>C	
M4	-	++	N>C	-

<sup>a</sup> ++, 50-100 % wild-type (wt); +, 5-50 % wt; -, < 5 % wt;

<sup>b</sup> ++, comparable to wt; +, 30-60 % wt; -, 5-20 % wt -, no detectable phosphorylation; nd, not done;

<sup>c</sup> ?, not detected by immunofluorescence; nd, not done;

<sup>d</sup> ++, highly trans-dominant; +, moderately trans-dominant; -, not detectably trans-dominant

Table 1 (continued)

Phenotypic analysis of HIV-1 <u>rev</u> gene mutants					
	Clone	Rev <sup>a</sup> function	Phosphorylation <sup>b</sup>	Sub-cellular <sup>c</sup> localization	Trans-dominant <sup>d</sup> repression
5	M5	-	±	C>N	-
	M6	-	-	C>N	-
10	M7	-	++	N>C	-
	M8	++	++	N>C	
	M9	++	++	N	
15	M10	-	++	N	++
	M11	++	++	N	
	M12	++	+	N	
20	M13	++	++	N	
	M14	++	++	N	
	Δ1/2	++	±	N	
	Δ1/3	-	-	N>C	-
25	Δ9/14	-	nd	nd	+
	Δ10/14	-	±	N	+
	Δ11/14	++	±	N	
	Δ12/14	++	±	N	
	Δ13/14	++	++	N	

<sup>a</sup> ++, 50-100 % wild-type (wt); +, 5-50 % wt; -, < 5 % wt;<sup>b</sup> ++, comparable to wt; +, 30-60 % wt; ±, 5-20 % wt; -, no detectable phosphorylation; nd, not done;<sup>c</sup> ?, not detected by immunofluorescence; nd, not done;<sup>d</sup> ++, highly trans-dominant; +, moderately trans-dominant; -, not detectably trans-dominant

30 [0125] The analysis summarized in Table 1 identified four missense mutations which resulted in diminished phosphorylation. Of these, M2 and M12 had a moderate effect on phosphate incorporation (-30 % and -60 % inhibition, respectively) while M5 and M6 dramatically reduced the level of phosphate incorporation. The possible reasons for the dramatic effect of the M5 and M6 mutations (which do not affect any serine residues) on phosphorylation of rev will be discussed in more detail below.

35 [0126] To further localize the phosphate receptor serine residues in Rev, a study of the level of phosphorylation of the deletion mutants (pΔ) (Fig. 8C, lanes 15-20) was performed. This analysis revealed that the pΔ13/14 mutation was normally phosphorylated while the pΔ12/14 deletion, and the larger C-terminal deletions, displayed only a low level of phosphorylation (-90 % inhibition). Similarly, the pΔ1/2 Rev mutant, which was effectively labelled with [<sup>35</sup>S]-cysteine, also displayed a low level of [<sup>32</sup>P]-Pi incorporation (-90 % inhibition).

40 [0127] It is unclear why deletions that extend to the site of the M2 and M12 mutations had a more drastic effect on the level of phosphorylation than the missense mutations themselves. However, these results are consistent with the hypothesis that the Rev protein contains two primary sites of serine phosphorylation, one located at residue 8 (M2) and the second at residue 99 (M12). In any case, the mutants which lack these residues (i.e., pM2, pΔ1/2, pM12, pΔ12/14) display approximately wild-type levels of Rev activity (Fig. 8B, Fig. 9). It is therefore concluded that phosphorylation of Rev is not essential for the trans-activation function of the HIV-1 regulatory protein in transfected cells.

#### Example 8: Nuclear localization of Rev

50 [0128] That the Rev protein is predominantly localized to the nuclei, particularly the nucleoli of expressing cells, was confirmed by analysis of the mutants using indirect immunofluorescence. The resulting phase contrast and corresponding immunofluorescence photographs of fixed, transfected COS cell cultures are shown in Figure 10.

[0129] The technique of indirect immunofluorescence used to localize the Rev protein within the transfected COS cell was that described in B.R. Cullen, Meth. Enzymol. 152 [1987] 684 and B.R. Cullen, J. Virol. 62 [1988] 2498 except that a modified paraformaldehyde-based cell fixation procedure was employed (Ruben et al., J. Virol. 53 [1989] 1-8). Specifically, the cells were treated with rabbit polyclonal anti-Rev peptide antiserum followed by rhodamine conjugated goat anti-rabbit IgG.

[0130] The primary rabbit anti-Rev antibody was used at a 1:800 dilution. REV1/20 antibody was used for analysis

of the majority of Rev mutants, with the exception of cultures transfected with the pM1, pM2, pM3, pΔ1/2 and pΔ1/3 vectors. REV27/51 antibody was used for these. The second antibody, rhodamine-conjugated goat anti-rabbit IgG (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA), was used at a 1:50 dilution.

[0131] The Rev mutants displayed four categories of subcellular localization as indicated in the Figure. The categories were: N, nuclear/nucleolar with no detectable cytoplasmic expression; N > C, slight cytoplasmic expression; N ≥ C, clear cytoplasmic expression with some nuclear concentration; C > N, random distribution within the cell. Representative examples of these distributions are shown in the Figure with the Rev proteins depicted being indicated in the upper right corner of the lower panel of pictures. The localization of each Rev mutant detected by this assay is set-forth in Table 1.

[0132] As shown, the majority of mutants displayed a fully wild-type subcellular localization (N), including the trans-activation negative clone pM10 (Fig. 10D). However, several mutants yielded a very low but detectable level of cytoplasmic fluorescence as typified by pM4 (Fig. 10F). This phenotype did not clearly correlate with biological activity, as both active mutants (pM3, pM8) and inactive mutants (pM4, pM7) displayed this property. Additionally, one fairly extensive deletion mutant, pΔ1/3, displayed a subcellular localization intermediate between the wild-type pattern and the pattern induced by mutations in the basic domain of Rev (N ≥ C, Fig. 10H). This deletion is, however, not located close to the basic domain. While the reason for this aberrant localization is unclear, it does correlate with the lack of biological activity observed for pΔ1/3.

[0133] Mutation of the arginine rich domain of Rev (pM5, pM6) which displays homology to known nuclear localization signals, resulted in a high level of cytoplasmic Rev protein (C > N). These proteins, however, were not excluded from the cell nucleus (Fig. 10J), suggesting that the basic domain of Rev is, in fact, a nuclear localization signal.

[0134] It is of interest to recall that pM5 and pM6 were not significantly phosphorylated *in vivo* despite retaining the sites proposed above as acceptors for phosphorylation. This may be because the kinase responsible for the phosphorylation of Rev is confined to the cell nucleus. Thus, it appears possible that inappropriate subcellular localization of the pM5 and pM6 Rev mutants is responsible for their low level of phosphorylation.

#### Example 9: Trans-dominant repression of Rev function

[0135] Rev mutants which had lost the ability to trans-activate HIV-1 structural gene expression were examined for their ability to inhibit in trans the function of the wild-type Rev protein.

[0136] COS cells (35 mm) were co-transfected with 250 ng of the indicator construction pgTAT and: 290 ng pBC12/CMV (negative control) (Fig. 11A, lane 1); 40 ng pcREV (low level), 250 ng pBC12/CMV (lane 2); 290 ng pcREV (high level) (lane 3); 40 ng pcREV, 250 ng pM4 (lane 4); 40 ng pcREV, 250 ng pM7 (Lane 5); 40 ng pcREV, 250 ng pM10 (lane 6). Sixty hours after transfection, the cultures were labelled with [<sup>35</sup>S]-cysteine and subjected to immunoprecipitation analysis using rabbit anti-Tat antisera.

[0137] As shown in Figure 11A, pM4 (lane 4) and pM7 (lane 5) had little effect on the activity of the wild-type Rev protein as measured by the induction of 72 aa Tat expression, whereas pM10 (lane 6) appeared to completely inhibit Rev function. This suggests that pM10 encodes a specific inhibitor of HIV-1 rev gene function.

[0138] In order to demonstrate that pM10 indeed acts by specifically preventing the cytoplasmic expression of the unspliced HIV-1 mRNA which encodes the 72 aa form of tat, the S1 nuclease protection assay of Malim et al., (1988), supra was employed. This assay (Fig. 11B) quantitates the level of spliced (S) and unspliced (U) tat mRNA expressed in the cytoplasm of COS cells (100 mm) transfected with: 2.75 µg pBC12/CMV + 2.5 µg pcREV (Lane 1); 2.5 µg pgTAT + 2.75 µg pBC12/CMV (Lane 2); 2.5 µg pgTAT + 0.25 µg pcREV + 2.5 µg pBC12/CMV (Lane 3); 2.5 µg pgTAT + 2.75 µg pcREV (Lane 4); 2.5 µg pgTAT + 0.25 µg pcREV + 2.5 µg pM10 (Lane 5); 2.5 µg pgTAT + 0.25 µg pcREV + 2.5 µg pΔ10/14 (Lane 6). As shown, total input DNA was maintained at a total of 5.25 µg by inclusion of the parental expression vector pBC12/CMV as a negative control.

[0139] At 60 hours after transfection, cytoplasmic RNA was harvested for analysis and 5 µg aliquots were used in the S1 nuclease protection assay. The DNA probe used herein was a 798 basepair probe end-labelled at an Xhol site located within the first coding exon of tat using Klenow DNA polymerase (Malim et al. [1988] supra). The probe (I) was designed to quantitate the level of both unspliced (U) and spliced (S) cytoplasmic tar mRNA in the transfected COS culture. Using this probe, spliced (S) tat mRNA is predicted to rescue a 202 nt probe fragment while unspliced (U) tat mRNA is predicted to rescue a 506 nt fragment. The relative level of unspliced RNA in each lane was quantitated by densitometry using an LKB soft laser scanner. The results, as visualized in Figure 11B, are: Lane 2: 14 % unspliced; Lane 3: 63 % unspliced; Lane 4: 82 % unspliced Lane 5: 22 % unspliced; Lane 6: 24 % unspliced.

[0140] As expected spliced tat mRNA predominates in the cytoplasm of cells transfected with pgTAT alone (Fig. 11B, Lane 2) while unspliced tat mRNA is the dominant cytoplasmic species in the cytoplasm of cells that coexpress the HIV-1 Rev protein (Figure 11B, Lanes 3 and 4). However, coexpression of pgTAT with both pcREV and pM10 restored the cytoplasmic predominance of the spliced form of tat mRNA (Figure 11B, Lane 5).

[0141] Although the total level of RNA loaded in Lanes 5 and 6 appear somewhat low, it is thus nevertheless apparent

that pM10 (Lane 5) was able to selectively inhibit the Rev induced cytoplasmic expression of unspliced tat mRNA from the pgTAT vector. Indeed, the relative level of unspliced tat mRNA detected in the presence of both pcREV and pM10 is comparable to the level observed in the absence of Rev.

[0142] The same pattern is apparent for pΔ10/14 (Fig. 11B, Lane 6). These results additionally demonstrate that a rev gene deletion extending 3' to the M10 mutation (pΔ10/14) also encodes a trans-repressor of Rev function. A more extensive deletion which extends through the site of the M10 mutation, termed pΔ9/14, also displayed a dominant negative phenotype (Table 1). However, a deletion which extended to the site of the M8 mutation was no longer trandominant (data not shown).

#### 10 Example 10: pM10 Rev mutant is a competitive inhibitor of rev function

[0143] The experimental results presented in Figure 11A and 11B demonstrate that pM10 can repress wild-type Rev function when present in *trans*. However, these experiments were performed in the presence of a large excess of pM10. To more accurately quantitate the effectiveness of the *trans*-inhibition of Rev function, the ability of increasing levels 15 of pM10 to inhibit the rescue of the pHIV-1Δrev provirus mutant by a single level of pcREV was analyzed. This experiment also tested the effect of increasing levels of the pM4 and pΔ10/14 Rev mutants, as well as the effect of simply increasing the level of expression of wild-type Rev itself.

[0144] COS cell cultures (35 mm) were co-transfected with 25 ng of pHIV-1Δrev and 50 ng of pcREV, with an increasing fold molar excess of either pcREV (▼), pM4 (Δ), pΔ10/14 (○) or pM10 (■), as indicated in Figure 12, i.e., 10 fold means co-transfection of 500 ng of the indicated plasmid construction. Total input DNA was maintained at a total 20 of 587.5 ng by inclusion of the parental expression vector pBC12/CMV as a negative control. A SEAP gene expression vector was co-transfected as an internal control (12.5 ng/culture). The supernatant media were sampled at 65 hours and assayed by measurement of the level of supernatant p24 Gag expression.

[0145] The results of this assay are presented in Figure 12 relative to the level of p24 expression obtained in the 25 absence of any competing rev vector, a level defined as 1.00. All values are expressed relative to the p24 Gag expression level observed in the culture transfected with 25 ng pHIV-1Δrev, 50 ng pcREV, 12.5 ng pBC12/RSV/SEAP and 500 ng pBC12/CMV. This control culture (●), which forms the basal value against which the competitive effects of the added Rev mutants were measured, was arbitrarily assigned a level of 1.00 unit of p24 Gag expression. The values presented herein are corrected for the slight variability observed in supernatant SEAP levels (mean SEAP activity was 30 1.00 ± 0.27 with a range of 1.28 to 0.72).

[0146] As depicted, increasing the level of transfection of the wild-type rev expression vector pcREV was found to exert a mildly positive effect on viral replication, leading maximally to an -70 % increase in the release of p24 Gag into the media. Co-transfection of the pM10 vector, in contrast, had a dramatically inhibitory effect on HIV-1 structural gene expression. The pattern of inhibition obtained is that expected for a competitive inhibitor of Rev function which displays 35 the same affinity as wild-type Rev for its biological target. Thus, an equimolar amount of pM10 reduced p24 Gag expression -2 fold, a 2fold excess of pM10 reduced expression -3 fold, a 5fold excess -6 fold while a 10fold excess reduced p24 Gag expression by -93 %.

[0147] In addition to pM10, co-transfection of pΔ10/14 also reduced p24. Gag expression, however, this large deletion 40 mutant of Rev was not as effective an inhibitor as pM10. It appears likely that the severely truncated protein expressed by pΔ10/14 is a less effective competitor because it lacks sequences which enhance the binding of Rev to its biological target.

[0148] Finally, co-transfection of pM4 also had an inhibitory effect, although it was slight, less than two fold (32 %), at the maximum dose used. This effect is thought to arise from an activity (squelching) unrelated to RRE binding.

#### 45 Example 11: Domain structure of the HIV-1 Rev trans-activator

[0149] As discussed above, transient gene expression analysis in transfected cells to assess the biological activity of a series of missense and deletion mutants of the HIV-1 trans-acting gene product Rev was used. These results evidence the possible existence of two functional domains within Rev, as depicted schematically in Figure 12A, wherein 50 S constitutes a splice site. Moreover, these two domains could be essential for *trans*-activation (cross-hatched).

[0150] The first of these domains (the RNA binding domain) defined by the four missense mutants pM4, pM5, pM6 and pM7, extends over about a 35 amino acid region between about amino acid position 10 and about amino acid position 68 of wild-type Rev and contains a highly basic sequence element which is essential for the nuclear localization 55 of Rev. It also contains a nuclear localization (NL) signal (shaded). Mutants altered in this domain display a recessive negative phenotype.

[0151] In contrast, mutations within the second domain (the activation domain), which is centered approximately on amino acid residue 79, and defined i.a. by the missense mutant pM10 and the deletion mutants pΔ9/14 and pΔ10/14, also result in a loss of Rev function but, remarkably, the negative phenotype displayed by these mutants is trans-

dominant. Two regions of Rev (hatched in Figure 12A) appear to be dispensable for protein function. As depicted herein, mutations in the Rev activation domain render Rev defective and result in the production of proteins which competitively inhibit wild-type Rev function. This trans-repression is sufficient to markedly reduce or suppress the replication of HIV-1 in transfected cells. The molecular basis for the dominant negative phenotypes displayed by pM10 and the related deletion mutants is not known yet. However, the observation that both missense (M10) and deletion ( $\Delta 9/14$ ,  $\Delta 10/14$ ) mutants are able to inhibit Rev function in trans does suggest that the loss, rather than the acquisition, of an attribute is responsible. One possibility is that defective Rev protein molecules might be able to form mixed multimers with wild-type Rev protein subunits and hence inhibit the function of the wild-type protein in a transdominant manner. It is not, however, currently known whether Rev functions as a monomer or as a multimer in vivo. An alternative hypothesis, based on earlier work involving the functional dissection of a number of prokaryotic and eukaryotic transcription factors, is that transcriptional trans-activators bear two distinct functional domains, a specific "binding domain" that directs the protein to its appropriate target substrate, and an "activation domain" that permits the functional consequence of the binding event, in this case transcriptional activation, to be displayed. In several systems, the binding domain has been shown to consist of a sequence-specific DNA binding element; however, in at least one case, that of the herpes simplex virus type 1 (HSV-1) trans-activator VP16, it appears that the binding domain instead mediates a specific interaction with a cellular transcription factor which in turn binds to target sequences in the HSV-1 genome. Importantly, mutation of the binding domain tends to result in a negative phenotype which is recessive at moderate levels of expression. In contrast, mutation or deletion of the activating domain of a transcription factor may result in mutants with a dominant negative phenotype. These mutants, which retain an intact binding domain, are believed to compete with the wild-type trans-activator for binding to the appropriate cellular target, yet are incapable of activating transcription once binding has occurred. In the case of the HSV-1 VP16 protein, overexpression of such a transdominant mutant has been shown to inhibit wild-type VP16 function effectively, and hence to preclude replication of HSV-1 in normally permissive cells.

[0152] Although the rev gene product is a posttranscriptional trans-regulator of gene expression it appears reasonable that the concept of two distinct functional domains should also be applicable in this case. In particular, Rev functions in a highly sequence-specific manner, via a direct interaction (M.H. Malim et al., *Cell* 60 [1990] 675-683) with its RNA target sequence, the RRE, and must therefore contain sequences that confer this specificity. Once binding has occurred, this event must be translated into an activation event, in this case nuclear export of the incompletely spliced RNAs that encode the HIV-1 structural proteins. Mutations in this latter domain might thus result in competitive inhibitors of wild-type Rev function. This is the phenotype observed for the pM10 and p $\Delta$ 10/14 mutants of Rev and these mutants may indicate the existence of a discrete activation domain. Conversely, the second, more N-terminal essential region of the Rev protein defined by this mutational analysis may serve the same function as the "binding domains" defined in several transcription factors. Mutants altered in this domain (e.g., pM4, pM7) do in fact display a generally recessive negative phenotype, although a low but significant inhibition is observed at high expression levels. Further transdominant mutants have also been found (see Figure 5A and Examples 11a and 11b) which allow the localization of the Rev activation domain to be refined as extending from about amino acid position 68 to about amino acid position 90, particularly from about position 78 to about position 86 and especially from about position 78 to about position 83 or 84 of wild-type Rev.

#### 40 Example 11a: Further transdominant HIV-1 Rev mutants

[0153] Further HIV-1 rev mutants have been prepared analogously to the procedures described above under 6.2. They are designated and characterized as appears in Figure 5A and in Table 2. The *in vivo* phenotype has been determined according to M.H. Malim et al., *Cell* 58 [1989] 205-214 (all assays were internally controlled for transfection efficiencies).

[0154] In addition to those found as described under Examples 4 to 11, above, the following further mutants have been found to transdominantly inhibit the wild-type HIV-1 Rev function: pM21, pM22, pM27, pM28, pM29 and pM32.

Table 2

Phenotypic analysis of further HIV-1 <u>rev</u> gene mutants			
	Clone	Phenotype <sup>a</sup>	Transdominant repression <sup>b</sup>
5	pBC12/CMV (vector alone)		0
	pM15	++	
	pM16	++	
	pM17	++	
10	pM18	+	
	pM19	++	
	pM20	++	
	pM21	-	97
15	pM22	-	93
	pM23	++	
	pM24	++	
	pM25	++	
20	pΔ9/19	-	
	pΔ18/19	+	
	pΔ18/23	-	
	pΔ22/14	-	
	pΔ23/14	+	
25	pM27	-	92
	pM28	-	92
	pM29	-	91
	pH32	-	97
30	pM33	++	
	pM34	++	
	pM35	++	
	pM36	+	

<sup>a</sup> ++ 40-100 % (relative to wild-type Rev activity)

+ 5-39 %

- &lt; 5 %

<sup>b</sup> as % inhibition of wild-type Rev function, with a 10fold excess of mutant Rev over wild-type Rev**Example 11b: Effect on HIV-2 and SIV Rev function**

[0155] The multivalent potential of the transdominant HIV-1 rev gene mutants of Example 4 to 11 has been analyzed using the methodology already described above under 6.2. and in M.H. Malim et al., *Proc.Natl.Acad.Sci.U.S.A.* 86 [1989] 8222-8226. The results obtained show that at least mutant pM10 has the capability of transdominantly inhibiting not only the phenotypic expression of the HIV-1 rev gene, but additionally also HIV-2 rev and SIV<sub>mac</sub> rev gene function, as shown, e.g. for HIV-2 rev, by strong inhibition of HIV-2 Rev function when an excess of pM10 is expressed together with wild-type HIV-2 rev gene, through inhibition of unspliced mRNA and of 1-exon tat expression in the cytoplasm.

## 6.3.

**Example 12: Analyses of Rex function**

[0156] For testing rex mutants for Rex function (Fig. 14), each mutant DNA was cotransfected with pgTAX-LTR into COS cells using DEAE-dextran (B.P. Cullen, *Meth. Enzymol.* 152 [1987] 692-693). All plasmids were added at a concentration of 1.25 µg/ml. Forty-eight hours after transfection, the cells were metabolically labelled with <sup>35</sup>S-cysteine for 2 hours, cellular extracts prepared, and the samples were immunoprecipitated with the 0.5 alpha human monoclonal antibody that specifically reacts with the HTLV-I envelope protein. Immunoprecipitates were analyzed on SDS-10 % polyacrylamide gels.

[0157] For simultaneous analysis of HTLV-I Env, Tax and Rex protein production (Fig. 15), COS cells were cotrans-

fected with pgTAX-LTR (0.1 µg/ml) and the vectors encoding the mutant Rex proteins (1 µg/ml) or the wild-type pREX, pREV and pCMV-IL-2 vectors (1 µg/ml). Immunoprecipitation analyses of HTLV-I proteins used the following antibodies: Env, 0.5 alpha antibody; Tax, Tax-specific anti-peptide rabbit antisera (prepared by one of the inventors; can also be prepared according to W. Wachsman et al., *Science* 235 [1987] 674-677); Rex, Rex-specific anti-peptide rabbit antisera (prepared by one of the inventors; can also be prepared according to H. Siemi et al., *Cell* 55 [1988] 197-209). In each case, the radiolabeled cellular extract was used for the three immunoprecipitations and electrophoretic analyses; only the relevant region of each of the resultant autoradiograms is presented in each panel of Fig. 15.

[0158] For subcellular localization of HTLV-I Rex mutants by immunofluorescence (Fig. 16), COS cells were transfected with the indicated expression plasmids and fixed with paraformaldehyde 48 hours later. The cells were then sequentially stained with rabbit anti-Rex peptide antiserum (1:100 dilution) and goat anti-rabbit IgG conjugated to rhodamine as previously described (B.R. Cullen [1987] *supra*).

#### **Example 13: Inhibition of Rex and Rev function**

[0159] For analysis of the ability of rex mutants to inhibit function of the wild-type Rex protein (Fig. 17A), COS cultures were cotransfected with three plasmids including pgTAX-LTR (1.25 µg/ml), pREX (0.1 µg/ml) and 1 µg/ml of the Rex mutants (Lanes 1-6), pREX (Lane 7), pREV (Lane 8) or pCMV-IL-2 (Lane 9). Env production was analyzed by immunoprecipitation with the 0.5 alpha monoclonal antibody and electrophoresis through SDS-10 % polyacrylamide gels. For analysis of inhibition of the function of HIV-1 Rev protein, COS cells were cotransfected with pgTAT, pREV and a 10-fold molar excess of pBC/CMV-IL-2 or the M6, M7 and M13 transdominant Rex mutants. After 48 hours of culture and biosynthetic labeling with <sup>35</sup>S-cysteine, cellular extracts were assayed by immunoprecipitation for Rev-induced production of the truncated 72 amino acid form of the Tat protein (Lane 2). At a 10:1 molar ratio, the M6, M7 and M13 (Lanes 3-5) **mutants completely inhibited the action of the HIV-1 Rev protein** as only the full-length 86 amino acid form of the Tat protein was detected. For analysis of inhibition of replication of HIV-1, COS cells were cotransfected with the rev-deficient HIV-1 proviral plasmid pHXB2-Bam-p3 (M.R. Feinberg et al., *Cell* 46 [1986] 807-817) and pREX in the presence of the indicated fold excess of the M1, M6, M7, and M13 mutants. Total DNA concentration in the transfection cocktail was maintained at a constant level by the addition of varying amounts of the pBC/CMV-IL-2 parental vector. Three days after transfection, supernatant levels of the HIV-1 p24 Gag protein were measured by ELISA (Coulter Immunology kit). The M6, M7 and M13 mutants produced dose-related inhibition of HIV-1 p24 production while the recessive negative M1 mutant did not.

#### **7. PHARMACOLOGICAL ASPECTS**

[0160] HIV-1 is the predominant etiologic agent of AIDS; HTLV-I is causing i.a. ATL; HTLV-II is etiologically related to some cases of variant T-cell hairy cell leukemia. The HIV-1 Rev and the HTLV-I Rex trans-activators have been shown to be essential for viral replication in culture and Rev and Rex are therefore potential targets for chemotherapeutic intervention in afflicted patients.

[0161] Described herein are mutant forms of Rev and/or Rex that act as effective competitive inhibitors of wild-type Rev and/or Rex function in cells transfected with wild-type Rev or Rex and which, therefore, also function as effective inhibitors of HIV-1 and/or HTLV-I and/or HTLV-II replication. These mutants could thus be used to protect the lymphoid cells of patients exposed to infection. An indication that this approach can be expected to be practicable is the observation that expression of an analogous transdominant derivative of the essential VP16 trans-activator of HSV-1 can effectively confer resistance to HSV-1 infection on a normally susceptible cell population (A.D. Friedman et al., *Nature* 335 [1988] 452-454). Further, corresponding transgenic mice appear to be immune to infection with HSV-1.

[0162] Mutant rex and rev genes encoding transdominant repressors of Rex or Rev are thus indicated for use as "intracellular immunogens" for the treatment of diseases caused by HTLV-I or by HTLV-II or, respectively, of HIV-1-induced diseases including AIDS and ARC (ARC). Further, since at least some of the transdominant Rex mutant proteins of the invention have the particular attribute of being able to inhibit both HTLV-I Rex and HIV-1 Rev protein action, they are thus indicated for use in the treatment of infections by both virus types. This property may be of particular value in patients coinfected with more than one of these viral pathogens or in those whose infection has not been distinguished between these two agents.

[0163] The existence of therapeutic agents effective on more than one viral species appears to have been nowhere disclosed prior to the present invention. In view of its broad applicability the above concept appears to be indicated not only in the therapy of the diseases caused by viral species encoding Rev and Rex but also in further viral diseases caused by organisms having genes similarly regulated.

[0164] The invention is thus indicated for use in the prophylaxis and therapy of viral, particularly retroviral diseases such as ATL (adult T-cell leukemia), AIDS (acquired immunodeficiency syndrome), ARC (AIDS-related syndrome or complex), SIV (simian immunodeficiency virus) such as SIV<sub>mac</sub>, FIV (feline immunodeficiency virus), EIAV

(equine infectious anemia virus), visna virus and bovine immunodeficiency virus infections, especially human retroviral diseases, more especially human retroviral diseases caused by pathogens regulated by the rex or rev gene or equivalents thereof, such as ATL, AIDS and ARS (ARC).

[0165] Of particular benefit is thereby the multivalent aspect of the repressor effect since it is of advantage in the treatment of multiple, especially double infection by virus, such as is often seen in i.v. drug users coinfected by HIV-1 and HTLV-I, or in treatment in situations of single infection with increased risk of further infection, such as in HIV infection, or in prophylaxis in situations where it is desired to protect against infection by a spectrum of different viral species.

[0166] This multivalent aspect, while normally expected to be most effective in the inhibition of somewhat related viruses of one particular type, e.g. retroviral viruses, is not necessarily restricted to closely related viruses, such as either DNA virus or RNA (retro-)virus: interactions are known to exist in levels of infectivity between DNA viruses and retroviruses, such as between HIV-1 and JC virus, a human papovavirus (H. Gendelman et al., Proc.Natl.Acad.Sci. USA 83 [1986] 9759-9763; H. Tada et al., ibid. 87 [1990] 3479-3483) and common regulatory mechanisms may thus well be at work in phylogenetically more distant viral species on which the above principles of multivalent transdominance could be applied.

[0167] The therapeutic potential of the invention is immediately apparent, since the repression of e.g. the Rex function of HTLV-I and the Rev function of HIV-1 blocks viral replication, thus preventing the formation of infective virus particles, and is thus expected to perpetuate the latent stage of infection. Thus the cells of subjects already infected with the HIV-1 virus but also having, integrated into their genome, the gene for a transdominant repressor would remain functional and the subjects indefinitely free of symptoms of disease, without the need for long-term therapy.

[0168] Viewed in this light the genes according to the invention are pharmaceuticals in themselves, for single or multiple administration either directly in vivo or indirectly in vitro, preferably as part of a vector, e.g. a retroviral or plasmid vector, in a form suitable for achieving delivery in a functional form into target mammalian cells; for example insertion of genes that encode such transdominant inhibitors of viral replication may be effected in vitro into cells of patients by direct implantation into the genome of lymphoid cells derived from infected individuals and these cells may be administered to the donor patient after insertion has been effected. Since HTLV-I and HTLV-II as well as HIV-1 replicate in various types of T-cells, the diseases they cause would appear to be particularly suited.

[0169] One application of this would thus parallel the gene therapy concept disclosed in e.g. T. Friedmann, Science 244 (16 June 1989) 1275 or P.M. Lehn, Bone Marrow Transplant 1 (1987) 243: hematopoietic stem cells are extracted from e.g. AIDS/ATL patients and cultivated in vitro, the mutated gene according to the invention, coding for a transdominant repressor for the function to be repressed, such as the Rev/Rex function, is implanted into these cells using retroviral vectors; the now viral-resistant progeny-producing stem cells are returned to the immune system of the original patient, where they are expected to proliferate in view of their acquired selective advantage over non-treated stem cells; in due time the population of hematopoietic cells will consist entirely of cells producing the transdominant factor and be virus-resistant.

[0170] Methods on how to effect this are already known in the art, see e.g. USP 4868116. Vectors, e.g. retroviral or plasmid vectors for delivering the mutated genes according to the invention into target mammalian cells such as bone marrow cells are disclosed or referred to in, e.g., Science 244 (16 June 1989) 1275. Thus, for example, various Rev and/or Rex transdominant genes are cloned into retroviral vector systems. After retroviral-mediated gene delivery into e.g. HIV-infected human cell lines the inhibitory effect of the transdominant mutants is readily ascertained by inhibition of viral production.

[0171] The above therapeutic concept is an example of intracellular immunization as envisaged in D. Baltimore, Nature 335 (1988) 395. In brief, the concept involves insertion of a gene that encodes a repressor of some vital function of a selected virus into the particular target cells which that virus infects (e.g., certain T-cells in the case of the virus causing AIDS). Application of this approach to therapy with a transdominant repressor of any virus is conditional upon establishment that potential vectors for genes encoding such mutant proteins and possible methods of inserting these vectors into the proper cells, which have been identified in model systems, constitute effective and safe intracellular delivery systems for human or animal applications. The concept can thus be put to the test of experimental verification only with difficulty in view of the ethical barriers presently preventing gene therapy. However the first such genetic experiments have just started, with non-therapeutic goals. It is to be expected that very shortly after the innocuity of the procedure has been demonstrated these pioneer experiments will be followed by similar trials with therapeutic goals, first in life-threatening conditions such as AIDS disease, and the present invention would appear to be well suited for early use in such trials (see T. Friedmann, Science 244 [16 June 1989] 1279, second column, "Infectious diseases").

[0172] A further mode of using the invention includes insertion not of a gene but of a repressor protein according to the invention into target cells. Administration e.g. orally or parenterally is effected in conventional manner in a form allowing intracellular penetration, such as by liposome-mediated delivery.

[0173] For these uses the exact dosage will of course vary depending upon the compound employed, mode of ad-

ministration and treatment desired; ascertaining the most suitable dosage in a particular situation is within the skill of the man of the art:

[0174] The invention is further indicated for use in the design and engineering of anti-viral drugs based on transdominance. A means has now been found for manipulating viral gene function which appears to be of general applicability for several viral species, although the structural basis therefor varies widely in the various viruses. This unexpected finding opens the way for studies aimed at designing further specific, possibly low molecular weight, possibly non-peptidic transdominant inhibitors of viral replication, in particular the design of inhibitors able to mimic the transdominant, i.e. primarily the RNA-binding domain in the mutant Rev or Rex proteins, such as low molecular weight inhibitors or neutralizing monoclonal antibodies.

[0175] It is to be understood that various combinations or changes in form and detail can be made to the invention as described above without departing from the scope of the present claims.

[0176] It is also to be understood that further mutants as described above, including mutants among the specific mutants already constructed and disclosed herein but which have not been characterized but may be characterized upon more detailed investigation as being transdominantly inhibitory and/or multivalent, and further mutants in accordance with the principles described above but not specifically disclosed herein, also fall within the scope of the present claims.

### Claims

20

#### Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LU, NL, SE

1. A DNA molecule coding for a mutant viral protein which is a modified form of a product of a gene essential for virus function and transdominantly represses the phenotypic expression of one or more of the following genes:

- 25 i) the wild-type rex gene of HTLV-I or HTLV-II, the mutant viral protein being modified from a wild-type form of the Rex protein; and
- 30 ii) the wild-type rev gene of HIV-1, HIV-2 or SIV, the mutant viral protein being modified from a wild-type form of the Rev protein.

2. A DNA according to claim 1, whereby the phenotypic expression of the rex gene of HTLV-I is repressed.

3. A DNA molecule according to claim 1, coding for an HTLV-I Rex protein having a mutation between amino acid positions 30 and 101 of the wild-type Rex protein of Figure 1, preferably between 82 and 97, especially between 87 and 94, or having a mutation between amino acid positions 59 and 121 of the wild-type Rex protein of Figure 1, preferably at position 59, 60, 64, 65, 119, 120 or 121.

4. A DNA molecule according to claim 3, from rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant no. 7 and Example 1).

5. A DNA molecule according to claim 2 whereby additionally the phenotypic expression of the HIV-1 rev gene is repressed.

45 6. The DNA molecule to claim 5, from rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant no. 7 and Example 1).

7. A DNA molecule according to claim 1, whereby the phenotypic expression of the rev gene of HIV-1, HIV-2 or SIV is repressed.

50 8. A DNA molecule according to claim 7, whereby HIV-1 rev gene phenotypic expression is repressed.

9. A DNA molecule according to claim 7 coding for an HIV-1 Rev protein having a mutation between amino acid positions 68 and 90 of the wild-type Rev protein of Figure 6, preferably between 78 and 86, especially between 78 and 83 or 84.

55

10. A DNA molecule according to claim 9, from rev-related pM32 (Figures 5A and 6, mutant pM32 and Example 11a).

11. A DNA molecule according to claim 9, from rev-related pM10 (Figures 5, 6 and 7, mutant M10 and Example 4).

12. A DNA molecule according to claim 1, from rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant No. 7 and Example 1).

5 13. A DNA molecule according to claim 1, from rev-related pM32 (Figures 5A and 6, mutant pM 32 and Example 11 a).

14. A DNA molecule according to claim 1, from rev-related PM10 (Figures 5, 6 and 7, mutant M10 and Example 4).

10 15. A DNA molecule according to claim 1 that encodes a transdominant repressor of the function of the HTL-I Rex protein, the repressor being modified from a wild-type form of the Rex protein by at least one transdominant negative mutation in the peptide domain between amino acid positions 59 and 121 of the wild-type Rex-protein, that encompasses the two regions that are most critical for Rex effector function, the repressor having substantially the nuclear localization activity of the wild-type form of the Rex protein.

16. A DNA molecule according to claim 11 coding for mutant protein M10.

15 17. A DNA molecule coding for mutant protein M10 according to claim 16, which is the wild-type gene of Figure 6, as modified to code for Asp at position 78 and Leu at position 79 of the wild-type Rev protein.

20 18. The DNA molecule according to claim 17 comprising nucleotides GATCTG coding for Asp at position 78 and Leu at position 79 of the wild-type Rev protein.

19. A mutant viral protein, wherein the mutant viral protein is a modified form of a product of a gene essential for virus function and which transdominantly represses the phenotypic expression of one or more of the following genes:

25 i) the wild-type rex gene of HTLV-I or HTLV-II, the mutant viral protein being modified from a wild-type form of the Rex protein; and  
ii) the wild-type rev gene of HIV-1, HIV-2 or SIV, the mutant viral protein being modified from a wild-type form of the Rev protein.

30 20. A protein according to claim 19, whereby the phenotypic expression of the rex gene of HTLV-I is repressed.

21. A protein according to claim 19 which is an HTLV-I Rex protein having a mutation between amino acid positions 30 and 101 of the wild-type Rex protein of Figure 1, preferably between 82 and 97, especially between 87 and 94; or having a mutation between amino acid positions 59 and 121 of the wild-type Rex protein of Figure 1, preferably at position 59, 60, 64 65, 119, 120 or 121.

35 22. A protein according to claim 21, encoded by rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant no. 7 and Example 1).

40 23. A protein according to claim 20 whereby additionally the phenotypic expression of the HIV-1 rev gene is repressed.

24. The protein according to claim 23, encoded by rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant no. 7 and Example 1).

45 25. A protein according to claim 19, whereby the phenotypic expression of the rev gene of HIV-1, HIV-2 or SIV is repressed.

26. A protein according to claim 25, whereby HIV-1 rev gene phenotypic expression is repressed.

50 27. A protein according to claim 25 which is an HIV-1 Rev protein having a mutation between amino acid positions 68 and 90 of the wild-type Rev protein of Figure 6, preferably between 78 and 86, especially between 78 and 83 or 84.

28. A protein according to claim 27, encoded by rev-related pM32 (Figures 5A and 6, mutant pM32 and Example 11a).

55 29. A protein according to claim 27, encoded by rev-related PM10 (Figures 5, 6 and 7, mutant M10 and Example 4).

30. A mutant viral protein according to claim 19, wherein the protein is encoded by rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant No. 7 and Example 1).

31. A mutant viral protein according to claim 19, wherein the protein is encoded by rev-related pM32 (Figures 5A and 6, mutant pM32 and Example 11a).

5 32. A mutant viral protein according to claim 19, wherein the protein is encoded by rev-related pM10 (Figures 5, 6 and 7, mutant M10 and Example 4).

10 33. A protein according to claim 20 of the function of the HTLV-I Rex protein, the repressor being modified from a wild type form of the Rex protein by at least one transdominant negative mutation between amino acid positions 59 and 121 in the peptide domain of the wild-type Rex protein, that encompasses the two regions that are most critical for Rex effector function, the repressor having substantially the nucleolar localization activity of the wild-type form of the Rex protein.

15 34. A protein according to claim 26 of HIV-1 Rev function comprising a first and a second domain, the first domain having substantially the specific binding function of wild-type HIV-1 Rev, the second domain being modified from wild-type HIV-1 Rev by one or more mutations.

20 35. A protein according to claim 26 of HIV-1 Rev function comprising a first domain having substantially the specific binding functions of wild-type Rev, said transdominant repressor not having the activation functions of wild-type HIV-1 Rev.

25 36. A protein according to claim 19 encoded by the DNA molecule as claimed in any one of claims 16, 17 or 18.

30 37. A process for the preparation of a DNA molecule according to any one of claims 1 to 18 which comprises isolating the corresponding wildtype gene form an appropriate expression system, putting this gene into an appropriate cloning system, introducing the desired mutation into the gene and recovering the resultant mutant gene from the clones having the desired mutation.

35 38. A process for the preparation of a protein according to any one of claims 19 to 36 which comprises expressing and amplifying a DNA molecule according to any one of claims 1 to 18 in an appropriate expression and amplification system and recovering the resultant product therefrom.

39. A pharmaceutical composition comprising a DNA molecule according to any one of claims 1 to 18 or a protein according to any one of claims 19 to 36 in a form suitable for achieving the desired prophylactic or therapeutic effect, together with a pharmaceutically acceptable carrier or diluent.

40 40. A method of inhibiting replication of HIV-1, HTLV-I or HTLV-II in vitro comprising introducing a DNA segment according to claim 15 into a cell having the ability to replicate one of these viruses and to express the DNA segment to produce a transdominant repressor according to claim 33 of HTLV-I Rex function.

41. A method of inhibiting HIV-1 replication in-vitro comprising introducing into a cell infected with HIV-1 a transdominant repressor according to claim 33 of HIV-1 Rev function.

42. A DNA molecule according to any one of claims 1 to 18 for use as a pharmaceutical.

43. A protein according to any one of claims 19 to 36 for use as a pharmaceutical.

44. A vector containing a DNA molecule according to any one of claims 1 to 18 in a form suitable for achieving delivery in a functional form into a target mammalian cell.

50 45. Use of a DNA molecule according to any one of claims 1 to 18 or of a vector as defined in claim 44 in the manufacture of a composition for use in gene therapy against viral infections.

46. Use according to claim 45 in the manufacture of a compositions for use in gene therapy to protect lymphoid cells of patients exposed to viral infection.

**Claims for the following Contracting States : ES, GR**

1. A process for the preparation of a DNA molecule coding for a mutant viral protein which is a modified form of a product of a gene essential for virus function and transdominantly represses the phenotypic expression of one or more of the following genes:

5            i) the wild-type rex gene of HTLV-I or HTLV-II, the mutant viral protein being modified from a wild-type form of the Rex protein; and  
 10          ii) the wild-type rev gene of HIV-1, HIV-2 or SIV, the mutant viral protein being modified from a wild-type form of the Rev protein, comprising isolating the corresponding wildtype gene from an appropriate expression system, putting this gene into an appropriate cloning system, introducing the desired mutation into the gene and recovering the resultant mutant gene from the clones having the desired mutation.

2. A process according to claim 1, whereby the phenotypic expression of the rex gene of HTLV-I is repressed.

15          3. A process according to claim 1 for the preparation of a DNA molecule as defined in claim 1 and coding for an HTLV-I Rex protein having a mutation between amino acid positions 30 and 101 of the wild-type Rex protein of Figure 1, preferably between 82 and 97, especially between 87 and 94; or having a mutation between amino acid positions 59 and 121 of the wild-type Rex protein of Figure 1, preferably at position 59, 60, 64., 65 and 119, 120 or 121.

20          4. A process according to claim 3 for the preparation of a DNA molecule as defined in claim 3, from rex-related pcRexM7 (Figures 1, 1A, 3 and 4, mutant no. 7).

25          5. A process according to claim 2 whereby additionally the phenotypic expression of the HIV-1 rev gene is repressed.

30          6. A process according to claim 2 for the preparation of a DNA molecule as defined in claim 4, from rex-related pcRexM7 \_ (Figures 1, 1A, 3 and 4, mutant no. 7).

35          7. A process according to claim 1, whereby the phenotypic expression of the rev gene of HIV-1, HIV-2 or SIV is repressed.

40          8. A process according to claim 7, whereby HIV-1 rev gene phenotypic expression is repressed.

45          9. A process according to claim 7 for the preparation of a DNA molecule coding for an HIV-1 Rev protein having a mutation between amino acid positions 68 and 90 of the wild-type Rev protein of Figure 6., preferably between 78 and 86, especially between 78 and 83 or 84.

50          10. A process according to claim 9 for the preparation of a DNA molecule as defined in claim 9, from rev -related pM32 (Figures 5A and 6, mutant pM32).

55          11. A process according to claim 9 for the preparation of a DNA molecule as defined in claim 9, from rev-related pM10 (Figures 5, 6, and 7, mutant M10).

60          12. A process according to claim 1 for the preparation of the DNA molecule from rex-related pcRexM7 (Figures 1, 1A, 2 and 4, mutant No. 7).

65          13. A Process according to claim 1 for the preparation of the DNA molecule from rev-related pM32 (Figures 5A and 6, mutant pM32).

70          14. A process according to claim 1 for the preparation of the DNA molecule from rev-related pM10 (Figures 5, 6 and 7, mutant M10).

75          15. A process for the preparation of a mutant viral protein as defined in claim 1 or 12 to 14 which comprises expressing an amplifying a DNA molecule as defined in claim 1 or 12 to 14 in an appropriate expression and amplification system and recovering the resultant product therefrom.

80          16. A process for the preparation of a pharmaceutical composition comprising mixing a DNA molecule or a protein as

defined in claim 1 in a form suitable for achieving the desired prophylactic or therapeutic effect, together with a pharmaceutically acceptable carrier or diluent.

17. A method of inhibiting HIV-1 replication *in vitro* comprising introducing into a cell infected with HIV-1 a transdominant 5 repressor of HIV-1 Rev function as defined in claim 1.

18. A process for the manufacture of a composition for use in gene therapy against viral infections comprising mixing a DNA molecule as defined in any one of claims 1 to 14 with a pharmaceutically acceptable carrier or diluent.

19. A process according to claim 18 for the manufacture of a composition for use in gene therapy to protect lymphoid 10 cells of patients exposed to viral infection.

20. A DNA molecule coding for a mutant viral protein which is a modified form of a product of a gene essential for virus 15 function and transdominantly represses the phenotypic expression of one or more of the following genes:

- i) the wild-type rex gene of HTLV-I or HTLV-II, the mutant viral protein being modified from a wild-type form of the Rex protein; and
- ii) the wild-type rev gene of HIV-1, HIV-2 or SIV, the mutant viral protein being modified from a wild-type form of the Rev protein.

21. A DNA molecule according to claim 20, whereby HIV-1 rev gene phenotypic expression is repressed.

22. A DNA molecule according to claim 20 coding for an HIV-1 Rev protein having a mutation between amino acid 25 positions 68 and 90 of the wild-type Rev protein of Figure 6, preferably between 78 and 86, especially between 78 and 83 or 84.

23. A DNA molecule according to claim 20 coding for mutant protein M10 (Figures 5,6 and 7, mutant M10 and Example 4).

24. A DNA molecule coding for mutant protein M10 according to claim 23, which is the wild-type gene of Figure 6, as 30 modified to code for Asp at position 78 and Leu at position 79 of the wild-type Rev protein.

25. The DNA molecule according to claim 24 comprising nucleotides GATCTG coding for Asp at position 78 and Leu at position 35 79 of the wild-type Rev protein.

26. A mutant viral protein, wherein the mutant viral protein is a modified form of a product of a gene essential for virus 40 function and which transdominantly represses the phenotypic expression of one or more of the following genes:

- i) the wild-type rex gene of HTLV-I or HTLV-II, the mutant viral protein being modified from a wild-type form of the Rex protein; and
- ii) the wild-type rev gene of HIV-1, HIV-2 or SIV, the mutant viral protein being modified from a wild-type form of the Rev protein.

27. A protein according to claim 26, whereby HIV-1 rev gene phenotypic expression is repressed.

28. A protein according to claim 26 encoded by the DNA molecule as claimed in any one of claims 23, 24 or 25.

29. A DNA molecule according to any one of claims 20 to 25 for use as a pharmaceutical.

30. A protein according to any one of claims 26 to 28 for use as a pharmaceutical.

31. A vector containing a DNA molecule according to any one of claims 20 to 25 in a form suitable for achieving delivery 50 in a functional form into a target mammalian cell.

32. Use of a DNA molecule according to any one of claims 20 to 25 or of a vector as defined in claim 31 in the manufacture of a composition for use in gene therapy against viral infections.

33. Use of a DNA molecule according to any one of claims 20 to 25 or of a vector as defined in claim 31 in the

manufacture of a composition for use in gene therapy to protect lymphoid cells of patients exposed to viral infection.

### Patentansprüche

5

#### Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LU, NL, SE

10 1. DNA-Molekül mit Codierung für ein Mutanten-Virusprotein, bei dem es sich um eine modifizierte Form eines Produkts eines für eine Virusfunktion essentiellen Gens handelt und das transdominant die phenotypische Expression eines oder mehrerer der folgenden Gene reprimiert.

15 i) das Wildtyp-rex-Gen von HTLV-I oder HTLV-II, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rex-Proteins modifiziert ist; und  
ii) das Wildtyp-rev-Gen von HIV-1, HIV-2 oder SIV, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rev-Proteins modifiziert ist.

20 2. DNA nach Anspruch 1, wobei die phenotypische Expression des rex-Gens von HTLV-I reprimiert wird.

25 3. DNA-Molekül nach Anspruch 1 mit Codierung für ein HTLV-I-Rex-Protein, das eine Mutation zwischen den Aminosäurepositionen 30 und 101 des Wildtyp-Rex-Proteins von Figur 1, vorzugsweise zwischen den Positionen 82 und 97, insbesondere zwischen den Positionen 87 und 94 oder eine Mutation zwischen den Aminosäurepositionen 59 und 121, vorzugsweise an der Position 59, 60, 64, 65, 119, 120 oder 121 des Wildtyp-Rex-Proteins von Figur 1 aufweist.

30 4. DNA-Molekül nach Anspruch 3 aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).

35 5. DNA-Molekül nach Anspruch 2, wobei zusätzlich die phenotypische Expression des HIV-1-rev-Gens reprimiert wird.

6. DNA-Molekül nach Anspruch 5 aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).

35 7. DNA-Molekül nach Anspruch 1, wobei die phenotypische Expression des rev-Gens von HIV-1, HIV-2 oder SIV reprimiert wird.

8. DNA-Molekül nach Anspruch 7, wobei die phenotypische Expression des rev-Gens von HIV-1 reprimiert wird.

40 9. DNA-Molekül nach Anspruch 7 mit Codierung für ein HIV-1-Rev-Protein, das eine Mutation zwischen den Aminosäurepositionen 68 und 90, vorzugsweise zwischen 78 und 86, insbesondere zwischen 78 und 83 oder 84 des Wildtyp-Rev-Proteins von Figur 6 aufweist.

45 10. DNA-Molekül nach Anspruch 9 aus dem rev-verwandten pM32 (Figuren 5A und 6, Mutante pM32 und Beispiel 11a).

11. DNA-Molekül nach Anspruch 9 aus dem rev-verwandten pM10 (Figuren 5, 6 und 7, Mutante M10 und Beispiel 4)

12. DNA-Molekül nach Anspruch 1 aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).

50 13. DNA-Molekül nach Anspruch 1 aus dem rev-verwandten pM32 (Figuren 5A und 6, Mutante pM32 und Beispiel 11a).

14. DNA-Molekül nach Anspruch 1 aus dem rev-verwandten pM10 (Figuren 5, 6 und 7, Mutante M10 und Beispiel 4).

55 15. DNA-Molekül nach Anspruch 1 mit Codierung für einen transdominanten Repressor der Funktion des HTL-1-Rex-Proteins, wobei der Repressor von einer Wildtyp-Form des Rex-Proteins durch mindestens eine transdominante negative Mutation in der Peptiddomäne zwischen den Aminosäurepositionen 59 und 121 des Wildtyp-Rex-Proteins, das die zwei Regionen umfasst, die für die Rex-Effektorfunktion am kritischsten sind, modifiziert ist und im

wesentlichen die nucleare Lokalisierungsaktivität der Wildtyp-Form des Rex-Proteins aufweist.

16. DNA-Molekül nach Anspruch 11 mit Codierung für das Mutantenprotein M10,
- 5 17. DNA-Molekül mit Codierung für das Mutantenprotein M10 nach Anspruch 16, wobei es sich um das Wildtyp-Gen von Figur 6 handelt, das so modifiziert ist, dass es für Asp an der Position 78 und für Leu an der Position 79 des Wildtyp-Rev-Proteins codiert.
- 10 18. DNA-Molekül nach Anspruch 17, das die Nucleotide GATCTG mit Codierung für Asp an der Position 78 und für Leu an der Position 79 des Wildtyp-Rev-Proteins umfasst.
- 15 19. Mutanten-Virusprotein, wobei das Mutanten-Virusprotein eine modifizierte Form eines Produkts eines für eine Virusfunktion essentiellen Gens ist und das transdominant die phenotypische Expression eines oder mehrerer der folgenden Gene reprimiert:
  - i) das Wildtyp-rex-Gen von HTLV-I oder HTLV-II, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rex-Proteins modifiziert ist; und
  - ii) das Wildtyp-rev-Gen von HIV-1, HIV-2 oder SIV, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rev-Proteins modifiziert ist.
- 20 20. Protein nach Anspruch 19, wobei die phenotypische Expression des rex-Gens von HTLV-1 reprimiert wird.
- 25 21. Protein nach Anspruch 19, das ein HTLV-I-Rex-Protein ist, das eine Mutation zwischen den Aminosäurepositionen 30 und 101 des Wildtyp-Rex-Proteins von Figur 1; vorzugsweise zwischen den Positionen 82 und 97, insbesondere zwischen den Positionen 87 und 94 oder eine Mutation zwischen den Aminosäurepositionen 59 und 121, vorzugsweise an der Position 59, 60, 64, 65, 119, 120 oder 121 des Wildtyp-Rex-Proteins von Figur 1 aufweist.
- 30 22. Protein nach Anspruch 21, codiert durch das rex-verwandte pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).
- 35 23. Protein nach Anspruch 20, wobei zusätzlich die phenotypische Expression des HIV-1-rev-Gens reprimiert wird.
24. Protein nach Anspruch 23, codiert durch das rex-verwandte pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).
- 40 25. Protein nach Anspruch 19, wobei die phenotypische Expression des rev-Gens von HIV-1, HIV-2 oder SIV reprimiert wird.
26. Protein nach Anspruch 25, wobei die phenotypische Expression des rev-Gens von HIV-1 reprimiert wird.
- 45 27. Protein nach Anspruch 25, das ein HIV-1-Rev-Protein ist, das eine Mutation zwischen den Aminosäurepositionen 68 und 90; vorzugsweise zwischen 78 und 86, insbesondere zwischen 78 und 83 oder 84 des Wildtyp-Rev-Proteins von Figur 6 aufweist.
28. Protein nach Anspruch 27, codiert durch das rev-verwandte pM32 (Figuren 5A und 6, Mutante pM32 und Beispiel 11a).
- 50 29. Protein nach Anspruch 27, codiert durch das rev-verwandte pM10 (Figuren 5, 6 und 7, Mutante M10 und Beispiel 4).
30. Mutanten-Virusprotein nach Anspruch 19, wobei das Protein durch das rex-verwandte pcRexM7 codiert ist (Figuren 1, 1A, 3 und 4, Mutante Nr. 7 und Beispiel 1).
- 55 31. Mutanten-Virusprotein nach Anspruch 19, wobei das Protein durch das rev-verwandte pM32 codiert ist (Figuren 5A und 6, Mutante pM32 und Beispiel 11a).
32. Mutanten-Virusprotein nach Anspruch 19, wobei das Protein durch das rev-verwandte pM10 codiert ist (Figuren 5, 6 und 7, Mutante pM32 und Beispiel 4).

5        33. Protein nach Anspruch 20 der Funktion des HTLV-I-Rex-Proteins, wobei der Repressor von einer Wildtyp-Form  
des Rex-Proteins durch mindestens eine transdominante negative Mutation zwischen den Aminosäurepositionen  
59 und 121 in der Peptiddomäne des Wildtyp-Rex-Proteins, das die zwei Regionen umfasst, die für die Rex-  
Effektorfunktion am kritischsten sind, modifiziert ist und im wesentlichen die nucleare Lokalisierungsaktivität der  
Wildtyp-Form des Rex-Proteins aufweist.

10      34. Protein nach Anspruch 26 der Funktion des HIV-1-Rev-Proteins, das eine erste und eine zweite Domäne umfasst,  
wobei die erste Domäne im wesentlichen die spezifische Bindungsfunktion des Wildtyp-HIV-1-Rev-Proteins auf-  
weist und die zweite Domäne durch eine oder mehrere Mutationen von dem Wildtyp-HIV-1-Rev-Protein modifiziert  
wird.

15      35. Protein nach Anspruch 26 der Funktion des HIV-1-Rev-Proteins, das eine erste Domäne umfasst, die im wesent-  
lichen die spezifischen Bindungsfunktionen des Wildtyp-Rev-Proteins aufweist, wobei der transdominante Repres-  
sor die Aktivierungsfunktionen des Wildtyp-HIV-1-Rev-Proteins nicht aufweist.

15      36. Protein nach Anspruch 19, codiert durch das DNA-Molekül gemäß einem der Ansprüche 16, 17 oder 18,

20      37. Verfahren zur Herstellung eines DNA-Moleküls nach einem der Ansprüche 1 bis 18 durch Isolieren des entspre-  
chenden Wildtyp-Gens aus einem geeigneten Expressionssystem, Einsetzen dieses Gens in ein geeignetes Klo-  
nierungssystem, Einführen der gewünschten Mutation in das Gen und Gewinnen des erhaltenen Mutanten-Gens  
aus den Klonen mit der gewünschten Mutation.

25      38. Verfahren zur Herstellung eines Proteins nach einem der Ansprüche 19 bis 36 durch Exprimieren und Amplifizieren  
eines DNA-Moleküls nach einem der Ansprüche 1 bis 18 in einem geeigneten Expressions- und Amplifikations-  
system und Gewinnen des erhaltenen Produkts daraus.

30      39. Pharmazeutische Zusammensetzung, die ein DNA-Molekül nach einem der Ansprüche 1 bis 18 oder ein Protein  
nach einem der Ansprüche 19 bis 36 in einer zum Erreichen des gewünschten prophylaktischen oder therapeu-  
tischen Effekts geeigneten Form zusammen mit einem pharmazeutisch akzeptablen Träger oder Verdünnungsmittel  
umfasst.

35      40. Verfahren zur Hemmung der Replikation von HIV-1, HTLV-1 oder HTLV-II in-vitro durch Einführen eines DNA-  
Segments nach Anspruch 15 in eine Zelle mit der Fähigkeit zur Replikation eines dieser Viren und zum Exprimieren  
des DNA-Segments zur Herstellung eines transdominanten Repressors nach Anspruch 33 einer HTLV-1-Rex-  
Funktion.

40      41. Verfahren zur Hemmung einer HIV-1-Replikation in-vitro durch Einführen eines transdominanten Repressors nach  
Anspruch 33 der HIV-1-Rev-Funktion in eine mit HIV-1-infizierte Zelle.

45      42. DNA-Molekül nach einem der Ansprüche 1 bis 18 zur Verwendung als Arzneimittel.

43. Protein nach einem der Ansprüche 19 bis 36 zur Verwendung als Arzneimittel.

45      44. Vektor, der ein DNA-Molekül nach einem der Ansprüche 1 bis 18 in einer Form enthält, die sich eignet, die Abgabe  
in einer funktionellen Form in eine Zielsäugetierzelle zu erreichen,

50      45. Verwendung eines DNA-Moleküls nach einem der Ansprüche 1 bis 18 oder eines Vektors gemäß Definition in  
Anspruch 44 bei der Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie gegen Virusin-  
fektionen.

50      46. Verwendung nach Anspruch 45 bei der Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie  
zum Schutz von lymphoiden Zellen von einer Virusinfektion ausgesetzten Patienten.

55      **Patentansprüche für folgende Vertragsstaaten : ES, GR**

1. Verfahren zur Herstellung eines DNA-Moleküls mit Codierung für ein Mutanten-Virusprotein, bei dem es sich um  
eine modifizierte Form eines Produkts eines für eine Virusfunktion essentiellen Gens handelt und das transdomi-

nant die phenotypische Expression eines oder mehrerer der folgenden Gene reprimiert:

- i) das Wildtyp-rex-Gen von HTLV-I oder HTLV-II, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rex-Proteins modifiziert ist; und
- ii) das Wildtyp-rev-Gen von HIV-1, HIV-2 oder SIV, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rev-Proteins modifiziert ist, wobei das Verfahren ein Isolieren des entsprechenden Wildtyp-Gens aus einem geeigneten Expressionssystem, das Einsetzen dieses Gens in ein geeignetes Klonierungssystem, das Einführen der gewünschten Mutation in das Gen und das Gewinnen des erhaltenen Mutantengens aus den Klonen mit der gewünschten Mutation umfaßt.

5                   2. Verfahren nach Anspruch 1, wobei die phenotypische Expression des rex-Gens von HTLV-I reprimiert wird.

10                 3. Verfahren nach Anspruch 1 zur Herstellung eines DNA-Moleküls gemäß Definition in Anspruch 1 und mit Codierung für ein HTLV-I-Rex-Protein, das eine Mutation zwischen den Aminosäurepositionen 30 und 101 des Wildtyp-Rex-Proteins von Figur 1, vorzugsweise zwischen den Positionen 82 und 97, insbesondere zwischen den Positionen 15                 87 und 94 oder eine Mutation zwischen den Aminosäurepositionen 59 und 121, vorzugsweise an der Position 59, 60, 64, 65, 119, 120 oder 121 des Wildtyp-Rex-Proteins von Figur 1 aufweist.

15                 4. Verfahren nach Anspruch 3 zur Herstellung eines DNA-Moleküls gemäß Definition in Anspruch 3 aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7).

20                 5. Verfahren nach Anspruch 2, wobei zusätzlich die phenotypische Expression des HIV-1-rev-Gens reprimiert wird.

25                 6. Verfahren nach Anspruch 2 zur Herstellung eines DNA-Moleküls gemäß Definition in Anspruch 4 aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 3 und 4, Mutante Nr. 7).

30                 7. Verfahren nach Anspruch 1, wobei die phenotypische Expression des rev-Gens von HIV-1, HIV-2 oder SIV reprimiert wird.

35                 8. Verfahren nach Anspruch 7, wobei die phenotypische Expression des rev-Gens von HIV-1 reprimiert wird.

40                 9. Verfahren nach Anspruch 7 zur Herstellung eines DNA-Moleküls mit Codierung für ein HIV-1-Rev-Protein, das eine Mutation zwischen den Aminosäurepositionen 68 und 90, vorzugsweise zwischen 78 und 86, insbesondere zwischen 78 und 83 oder 84 des Wildtyp-Rev-Proteins von Figur 6 aufweist.

45                 10. Verfahren nach Anspruch 9 zur Herstellung eines DNA-Moleküls gemäß Definition in Anspruch 9 aus dem rev-verwandten pM32 (Figuren 5A und 6, Mutante pM32),

50                 11. Verfahren nach Anspruch 9 zur Herstellung eines DNA-Moleküls gemäß Definition in Anspruch 9 aus dem rev-verwandten pM10 (Figuren 5, 6 und 7, Mutante M10).

55                 12. Verfahren nach Anspruch 1 zur Herstellung eines DNA-Moleküls aus dem rex-verwandten pcRexM7 (Figuren 1, 1A, 2 und 4, Mutante Nr. 7).

60                 13. Verfahren nach Anspruch 1 zur Herstellung eines DNA-Moleküls aus dem rev-verwandten pM32 (Figuren 5A und 6, Mutante pM32).

65                 14. Verfahren nach Anspruch 1 zur Herstellung eines DNA-Moleküls aus dem rev-verwandten pM10 (Figuren 5, 6 und 7, Mutante M10).

70                 15. Verfahren zur Herstellung eines Mutanten-Virusproteins gemäß Definition in Anspruch 1 oder 12 bis 14 durch Exprimieren und Amplifizieren eines DNA-Moleküls gemäß Definition in Anspruch 1 oder 12 bis 14 in einem geeigneten Expressions- und Amplifikationssystem und Gewinnen des erhaltenen Produkts daraus.

75                 16. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, das ein Vermischen eines DNA-Moleküls oder eines Proteins gemäß Definition in Anspruch 1 in einer zum Erreichen des gewünschten prophylaktischen oder therapeutischen Effekts geeigneten Form mit einem pharmazeutisch akzeptablen Träger oder Verdünnungsmittel umfaßt.

17. Verfahren zur Hemmung einer HIV-1-Replikation in-vitro durch Einführen eines transdominanten Repressors der HIV-1-Rev-Funktion gemäß Definition in Anspruch 1 in eine mit HIV-1-infizierte Zelle,

18. Verfahren zur Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie gegen Virusinfektionen durch Vermischen eines DNA-Moleküls gemäß Definition in einem der Ansprüche 1 bis 14 mit einem pharmazeutisch akzeptablen Träger oder Verdünnungsmittel.

19. Verfahren nach Anspruch 18 zur Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie zum Schutz von lymphoiden Zellen von einer Virusinfektion ausgesetzten Patienten.

20. DNA-Molekül mit Codierung für ein Mutanten-Virusprotein, bei dem es sich um eine modifizierte Form eines Produkts eines für eine Virusfunktion essentiellen Gens handelt und das transdominant die phenotypische Expression eines oder mehrerer der folgenden Gene reprimiert:

15      i) das Wildtyp-rex-Gen von HTLV-I oder HTLV-II, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rex-Proteins modifiziert ist; und  
ii) das Wildtyp-rev-Gen von HIV-1, HIV-2 oder SIV, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rev-Proteins modifiziert ist.

21. DNA-Molekül nach Anspruch 20, wobei die phenotypische Expression des rev-Gens von HIV-1 reprimiert wird.

22. DNA-Molekül nach Anspruch 20 mit Codierung für ein HIV-1-Rev-Protein, das eine Mutation zwischen den Aminosäurepositionen 68 und 90, vorzugsweise zwischen 78 und 86, insbesondere zwischen 78 und 83 oder 84 des Wildtyp-Rev-Proteins von Figur 6 aufweist.

23. DNA-Molekül nach Anspruch 20 mit Codierung für das Mutantenprotein M10 (Figuren 5, 6 und 7, Mutante M10 und Beispiel 4).

24. DNA-Molekül mit Codierung für das Mutantenprotein M10 nach Anspruch 23, wobei es sich um das Wildtyp-Gen von Figur 6 handelt, das so modifiziert ist, dass es für Asp an der Position 78 und für Leu an der Position 79 des Wildtyp-Rev-Proteins codiert.

25. DNA-Molekül nach Anspruch 24, das die Nucleotide GATCTG mit Codierung für Asp an der Position 78 und Leu an der Position 79 des Wildtyp-Rev-Proteins umfasst.

26. Mutanten-Virusprotein, wobei das Mutanten-Virusprotein eine modifizierte Form eines Produkts eines für eine Virusfunktion essentiellen Gens ist und das transdominant die phenotypische Expression eines oder mehrerer der folgenden Gene reprimiert:

40      i) das Wildtyp-rex-Gen von HTLV-I oder HTLV-II, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rex-Proteins modifiziert ist; und  
ii) das Wildtyp-rev-Gen von HIV-1, HIV-2 oder SIV, wobei das Mutanten-Virusprotein von einer Wildtyp-Form des Rev-Proteins modifiziert ist

27. Protein nach Anspruch 26, wobei die phenotypische Expression des HIV-1- rev-Gens reprimiert wird,

28. Protein nach Anspruch 26, codiert durch das DNA-Molekül nach einem der Ansprüche 23, 24 oder 25.

29. DNA-Molekül nach einem der Ansprüche 20 bis 25 zur Verwendung als Arzneimittel.

30. Protein nach einem der Ansprüche 26 bis 28 zur Verwendung als Arzneimittel.

31. Vektor, der ein DNA-Molekül nach einem der Ansprüche 20 bis 25 in einer Form enthält, die sich eignet, die Abgabe in einer funktionellen Form in eine Zielsäugetierzelle zu erreichen.

32. Verwendung eines DNA-Moleküls nach einem der Ansprüche 20 bis 25 oder eines Vektors gemäß Definition in Anspruch 31 bei der Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie gegen Virusinfektionen.

33. Verwendung eines DNA-Moleküls nach einem der Ansprüche 20 bis 25 oder eines Vektors gemäß Definition in Anspruch 31 bei der Herstellung einer Zusammensetzung zur Verwendung bei der Gentherapie zum Schutz von lymphoiden Zellen von einer Virusinfektion ausgesetzten Patienten.

5

## Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LU, NL, SE

10

1. Molécule d'ADN codant pour une protéine virale mutante qui est une forme modifiée d'un produit d'un gène essentiel pour la fonction virale et qui réprime de façon transdominante l'expression phénotypique d'un des gènes suivants ou de plusieurs d'entre eux:

15

- i) le gène rex de type sauvage de HTLV-I ou HTLV-II, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rex; et
- ii) le gène rev de type sauvage de HIV-1, HIV-2 ou SIV, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rev.

20

2. ADN selon la revendication 1, grâce auquel l'expression phénotypique du gène rex de HTLV-I est réprimée.

25

3. Molécule d'ADN selon la revendication 1, codant pour une protéine Rex de HTLV-I ayant une mutation entre les positions d'acide aminé 30 et 101 de la protéine Rex de type sauvage de la Figure 1, de préférence entre 82 et 97, en particulier entre 87 et 94, ou ayant une mutation entre les positions d'acide aminé 59 et 121 de la protéine Rex de type sauvage de la Figure 1, de préférence à la position 59, 60, 64, 65, 119, 120 ou 121.

30

4. Molécule d'ADN selon la revendication 3, issue de pcRexM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7 et Exemple 1).

35

5. Molécule d'ADN selon la revendication 2, grâce à laquelle en outre, l'expression phénotypique du gène rev de HIV-1 est réprimée.

6. Molécule d'ADN selon la revendication 5, issue de pcRexM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7 et Exemple 1).

40

7. Molécule d'ADN selon la revendication 1, grâce à laquelle l'expression phénotypique du gène rev de HIV-1, HIV-2 ou SIV est réprimée.

45

8. Molécule d'ADN selon la revendication 7, grâce à laquelle l'expression phénotypique du gène rev de HIV-1 est réprimée.

50

9. Molécule d'ADN selon la revendication 7, codant pour une protéine Rev de HIV-1 ayant une mutation entre les positions d'acide aminé 68 et 90 de la protéine Rev de type sauvage de la Figure 6, de préférence entre 78 et 86, en particulier entre 78 et 83 ou 84.

10. Molécule d'ADN selon la revendication 9, issue de pM32 apparenté à rev (Figures 5A et 6, mutant pM32 et Exemple 11a).

55

11. Molécule d'ADN selon la revendication 9, issue de pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10 et Exemple 4).

12. Molécule d'ADN selon la revendication 1, issue de pcRexM7 apparenté à rcx (Figures 1, 1A, 3 et 4, mutant N° 7 et Exemple 1).

60

13. Molécule d'ADN selon la revendication 1, issue de pM32 apparenté à rev (Figures SA et 6, mutant pM32 et Exemple 11a).

14. Molécule d'ADN selon la revendication 1, issue de pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10 et Exemple

4).

5        15. Molécule d'ADN selon la revendication 1, qui code pour un répresseur transdominant de la fonction de la protéine Rex de HTLV-1, le répresseur étant modifié à partir d'une forme de type sauvage de la protéine Rex par au moins une mutation négative transdominante dans le domaine peptidique compris entre les positions d'acide aminé 59 et 121 de la protéine Rex de type sauvage, qui englobe les deux régions qui sont les plus cruciales pour la fonction effectrice de Rex, le répresseur ayant essentiellement l'activité de localisation nucléaire de la forme de type sauvage de la protéine Rex.

10      16. Molécule d'ADN selon la revendication 11, codant pour la protéine mutante M10.

15      17. Molécule d'ADN codant pour la protéine mutante M10 selon la revendication 16, qui est le gène de type sauvage de la Figure 6, modifié pour coder pour Asp en position 78 et pour Leu en position 79 de la protéine Rev de type sauvage.

15      18. Molécule d'ADN selon la revendication 17, comprenant les nucléotides GATCTG codant pour Asp en position 78 et pour Leu en position 79 de la protéine Rev de type sauvage.

20      19. Protéine virale mutante, ladite protéine virale mutante étant une forme modifiée d'un produit d'un gène essentiel pour la fonction virale et qui réprime de façon transdominante l'expression phénotypique d'un des gènes suivants ou de plusieurs d'entre eux:

25      i) le gène rex de type sauvage de HTLV-I ou HTLV-II, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rex; et  
ii) le gène rev de type sauvage de HIV-1, HIV-2 ou SIV, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rcv.

30      20. Protéine selon la revendication 19, grâce à laquelle l'expression phénotypique du gène rex de HTLV-I est réprimée.

35      21. Protéine selon la revendication 19, qui est une protéine Rex de HTLV-I ayant une mutation entre les positions d'acide aminé 30 et 101 de la protéine Rex de type sauvage de la Figure 1, de préférence entre 82 et 97, en particulier entre 87 et 94; ou ayant une mutation entre les positions d'acide aminé 59 et 121 de la protéine Rex de type sauvage de la Figure 1, de préférence en position 59, 60, 64, 65, 119, 120 ou 121.

40      22. Protéine selon la revendication 21, codée par pcReaeM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7 et Exemple 1).

45      23. Protéine selon la revendication 20, grâce à laquelle en outre, l'expression phénotypique du gène rev de HIV-1 est réprimée.

45      24. Protéine selon la revendication 23, codée par pcRexM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7 et Exemple 1).

50      25. Protéine selon la revendication 19, grâce à laquelle l'expression phénotypique du gène rev de HIV-1, HIV-2 ou SIV est réprimée.

55      26. Protéine selon la revendication 25, grâce à laquelle l'expression phénotypique du gène rev de HIV-1 est réprimée.

55      27. Protéine selon la revendication 25, qui est une protéine Rev de HIV-1 ayant une mutation entre les positions d'acide aminé 68 et 90 de la protéine Rev de type sauvage de la Figure 6, de préférence entre 78 et 86, en particulier entre 78 et 83 ou 84.

55      28. Protéine selon la revendication 27, codée par pM32 apparenté à rev (Figures 5A et 6, mutant pM32 et Exemple 11a).

55      29. Protéine selon la revendication 27, codée par pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10 et Exemple 4).

55      30. Protéine virale mutante selon la revendication 19, ladite protéine étant codée par pcRexM7 apparenté à rex (Fi-

gures 1, 1A, 3 et 4, mutant n°7 et Exemple 1).

31. Protéine virale mutante selon la revendication 19, ladite protéine étant codée par pM32 apparenté à rev (Figures 5A et 6, mutant pM32 et Exemple 11a).

5 32. Protéine virale mutante selon la revendication 19, ladite protéine étant codée par pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10 et Exemple 4).

10 33. Protéine selon la revendication 20 ayant la fonction de la protéine Rex de HTLV-I, le répresseur étant modifié à partir d'une forme de type sauvage de la protéine Rex par au moins une mutation négative transdominante entre les positions d'acide aminé 59 et 121 dans le domaine peptidique de la protéine Rex de type sauvage, qui englobe les deux régions qui sont les plus cruciales pour la fonction effectrice de Rex, le répresseur ayant essentiellement l'activité de localisation nucléaire de la forme de type sauvage de la protéine Rex.

15 34. Protéine selon la revendication 26 ayant la fonction de la protéine Rev de HIV-1, comprenant un premier et un second domaine, le premier domaine ayant essentiellement la fonction de liaison spécifique de Rev de HIV-1 de type sauvage, le second domaine étant modifié à partir de Rev de HIV-1 de type sauvage par une ou plusieurs mutations.

20 35. Protéine selon la revendication 26 ayant la fonction de la protéine Rev de HIV-1, comprenant un premier domaine ayant essentiellement les fonctions de liaison spécifique de Rev de type sauvage, ledit répresseur transdominant n'ayant pas les fonctions d'activation de Rev de HIV-1 de type sauvage.

25 36. Protéine selon la revendication 19, codée par la molécule d'ADN telle que revendiquée dans l'une quelconque des revendications 16, 17 et 18.

30 37. Procédé pour la préparation d'une molécule d'ADN selon l'une quelconque des revendications 1 à 18, qui comprend les étapes consistant à isoler le gène de type sauvage correspondant à partir d'un système d'expression approprié, à placer ce gène dans un système de clonage approprié, à introduire la mutation désirée dans le gène et à récupérer le gène mutant résultant à partir des clones ayant la mutation désirée.

35 38. Procédé pour la préparation d'une protéine selon l'une quelconque des revendications 19 à 36, qui comprend l'expression et l'amplification d'une molécule d'ADN selon l'une quelconque des revendications 1 à 18 dans un système d'expression et d'amplification approprié et la récupération du produit résultant à partir de ce système.

40 39. Composition pharmaceutique comprenant une molécule d'ADN selon l'une quelconque des revendications 1 à 18 ou une protéine selon l'une quelconque des revendications 19 à 36 sous une forme appropriée pour l'obtention de l'effet prophylactique ou thérapeutique recherché, conjointement avec un véhicule ou diluant acceptable d'un point de vue pharmaceutique.

45 40. Procédé d'inhibition de la réplication de HIV-1, HTLV-I ou HTLV-II *in vitro*, comprenant l'introduction d'un segment d'ADN selon la revendication 15 dans une cellule ayant la capacité de répliquer un de ces virus et d'exprimer le segment d'ADN pour produire un répresseur transdominant selon la revendication 33 de la fonction de Rex de HTLV-I.

41. Procédé d'inhibition de la réplication de HIV-1 *in vitro*, comprenant l'introduction dans une cellule infectée par HIV-1 d'un répresseur transdominant selon la revendication 33 de la fonction de Rcv de HIV-1.

50 42. Molécule d'ADN selon l'une quelconque des revendications 1 à 18, destinée à être utilisée comme produit pharmaceutique.

43. Protéine selon l'une quelconque des revendications 19 à 36, destinée à être utilisée comme produit pharmaceutique.

55 44. Vecteur contenant une molécule d'ADN selon l'une quelconque des revendications 1 à 18, dans une forme appropriée permettant la délivrance sous une forme fonctionnelle dans une cellule de mammifère cible.

45. Utilisation d'une molécule d'ADN selon l'une quelconque des revendications 1 à 18 ou d'un vecteur tel que défini

dans la revendication 44 dans la fabrication d'une composition destinée à être utilisée en thérapie génique contre les infections virales.

46. Utilisation selon la revendication 45 dans la fabrication d'une composition destinée à être utilisée en thérapie 5 génique pour protéger les cellules lymphoïdes de patients exposés à une infection virale.

**Revendications pour les Etats contractants suivants : ES, GR**

1. Procédé pour la préparation d'une molécule d'ADN codant pour une protéine virale mutante qui est une forme modifiée d'un produit d'un gène essentiel pour la fonction virale et qui réprime de façon transdominante l'expression phénotypique d'un des gènes suivants ou de plusieurs d'entre eux:
  - i) le gène rex de type sauvage de HTLV-I ou HTLV-II, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rex; et
  - ii) le gène rev de type sauvage de HIV-1, HIV-2 ou SIV, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rev,

ledit procédé comprenant les étapes consistant à isoler le gène de type sauvage correspondant à partir d'un système d'expression approprié, à placer ce gène dans un système de clonage approprié, à introduire la mutation désirée dans le gène et à récupérer le gène mutant résultant à partir des clones ayant la mutation désirée.
2. Procédé selon la revendication 1, par lequel l'expression phénotypique du gène rex de HTLV-I est réprimée.
3. Procédé selon la revendication 1 pour la préparation d'une molécule d'ADN telle que définie dans la revendication 1 et codant pour une protéine Rex de HTLV-I ayant une mutation entre les positions d'acide aminé 30 et 101 de la protéine Rex de type sauvage de la Figure 1, de préférence entre 82 et 97, en particulier entre 87 et 94; ou ayant une mutation entre les positions d'acide aminé 59 et 121 de la protéine Rex de type sauvage de la Figure 1, de préférence à la position 59, 60, 64, 65 et 119, 120 ou 121.
4. Procédé selon la revendication 3 pour la préparation d'une molécule d'ADN telle que définie dans la revendication 3, à partir de pcRexM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7).
5. Procédé selon la revendication 2, par lequel en outre, l'expression phénotypique du gène rev de HIV-1 est réprimée.
6. Procédé selon la revendication 2 pour la préparation d'une molécule d'ADN telle que définie dans la revendication 4, à partir de pcRexM7 apparenté à rex (Figures 1, 1A, 3 et 4, mutant n°7).
7. Procédé selon la revendication 1, par lequel l'expression phénotypique du gène rev de HIV-1, HIV-2 ou SIV est réprimée.
8. Procédé selon la revendication 7, par lequel l'expression phénotypique du gène rev de HIV-1 est réprimée.
9. Procédé selon la revendication 7 pour la préparation d'une molécule d'ADN codant pour une protéine Rcv de HIV-1 ayant une mutation entre les positions d'acide aminé 68 et 90 de la protéine Rev de type sauvage de la Figure 6, de préférence entre 78 et 86, en particulier entre 78 et 83 ou 84.
10. Procédé selon la revendication 9 pour la préparation d'une molécule d'ADN telle que définie dans la revendication 9, à partir de pM32 apparenté à rev (Figures SA et 6, mutant pM32).
11. Procédé selon la revendication 9 pour la préparation d'une molécule d'ADN telle que définie dans la revendication 9, à partir de pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10).
12. Procédé selon la revendication 1 pour la préparation de la molécule d'ADN à partir de pcRexM7 apparenté à rex (Figures 1, 1A, 2 et 4, mutant n°7).
13. Procédé selon la revendication 1 pour la préparation de la molécule d'ADN à partir de pM32 apparenté à rev (Figures 5A et 6, mutant pM32).

14. Procédé selon la revendication 1 pour la préparation de la molécule d'ADN à partir de pM10 apparenté à rev (Figures 5, 6 et 7, mutant M10).

5        15. Procédé pour la préparation d'une protéine virale mutante telle que définie dans les revendications 1 ou 12 à 14, qui comprend l'expression et l'amplification d'une molécule d'ADN telle que définie dans les revendications 1 ou 12 à 14 dans un système d'expression et d'amplification approprié, et la récupération du produit résultant à partir de ce système.

10      16. Procédé pour la préparation d'une composition pharmaceutique comprenant le mélange d'une molécule d'ADN ou d'une protéine telle que définie dans la revendication 1 sous une forme appropriée pour l'obtention de l'effet prophylactique ou thérapeutique recherché, conjointement avec un véhicule ou diluant acceptable d'un point de vue pharmaceutique.

15      17. Procédé d'inhibition de la réplication de HIV-1 *in vitro*, comprenant l'introduction dans une cellule infectée par HIV-1 d'un répresseur transdominant de la fonction de Rev de HIV-1, tel que défini dans la revendication 1.

20      18. Procédé pour la fabrication d'une composition destinée à être utilisée en thérapie génique contre les infections virales, comprenant le mélange d'une molécule d'ADN telle que définie dans l'une quelconque des revendications 1 à 14 avec un véhicule ou diluant acceptable d'un point de vue pharmaceutique.

25      19. Procédé selon la revendication 18 pour la fabrication d'une composition destinée à être utilisée en thérapie génique pour protéger les cellules lymphoïdes de patients exposés à une infection virale.

30      20. Molécule d'ADN codant pour une protéine virale mutante qui est une forme modifiée d'un produit d'un gène essentiel pour la fonction virale et qui réprime de façon transdominante l'expression phénotypique d'un des gènes suivants ou de plusieurs d'entre eux:

- i) le gène rex de type sauvage de HTLV-I ou HTLV-II, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rex; et
- ii) le gène rev de type sauvage de HIV-1, HIV-2 ou SIV, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rev.

35      21. Molécule d'ADN selon la revendication 20, grâce à laquelle l'expression phénotypique du gène rev de HIV-1 est réprimée.

22. Molécule d'ADN selon la revendication 20, codant pour une protéine Rev de HIV-1 ayant une mutation entre les positions d'acide aminé 68 et 90 de la protéine Rev de type sauvage de la Figure 6, de préférence entre 78 et 86, en particulier entre 78 et 83 ou 84.

40      23. Molécule d'ADN selon la revendication 20, codant pour une protéine mutante M10 (Figures 5, 6 et 7, mutant M10 et Exemple 4).

24. Molécule d'ADN codant pour la protéine mutante M10 selon la revendication 23, qui est le gène de type sauvage de la Figure 6, modifié pour coder pour Asp en position 78 et pour Leu en position 79 de la protéine Rev de type sauvage.

45      25. Molécule d'ADN selon la revendication 24, comprenant les nucléotides GATCTG codant pour Asp en position 78 et Leu en position 79 de la protéine Rev de type sauvage.

50      26. Protéine virale mutante, ladite protéine virale mutante étant une forme modifiée d'un produit d'un gène essentiel pour la fonction virale et qui réprime de façon transdominante l'expression phénotypique d'un des gènes suivants ou de plusieurs d'entre eux:

- i) le gène rex de type sauvage de HTLV-I ou HTLV-II, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rex; et
- ii) le gène rev de type sauvage de HIV-1, HIV-2 ou SIV, la protéine virale mutante étant modifiée à partir d'une forme de type sauvage de la protéine Rev.

27. Protéine selon la revendication 26, grâce à laquelle l'expression phénotypique du gène rev de HIV-1 est réprimée.

28. Protéine selon la revendication 26 codée par la molécule d'ADN telle que revendiquée dans l'une quelconque des revendications 23, 24 et 25.

5 29. Molécule d'ADN selon l'une quelconque des revendications 20 à 25, destinée à être utilisée comme produit pharmaceutique.

10 30. Protéine selon l'une quelconque des revendications 26 à 28, destinée à être utilisée comme produit pharmaceutique.

31. Vecteur contenant une molécule d'ADN selon l'une quelconque des revendications 20 à 25 dans une forme appropriée permettant la délivrance sous une forme fonctionnelle dans une cellule de mammifère cible.

15 32. Utilisation d'une molécule d'ADN selon l'une quelconque des revendications 20 à 25 ou d'un vecteur tel que défini dans la revendication 31 pour la fabrication d'une composition destinée à être utilisée en thérapie génique contre les infections virales.

20 33. Utilisation d'une molécule d'ADN selon l'une quelconque des revendications 20 à 25 ou d'un vecteur tel que défini dans la revendication 31 pour la fabrication d'une composition destinée à être utilisée en thérapie génique pour protéger les cellules lymphoïdes de patients exposés à une infection virale.

25

30

35

40

45

50

55

**F I G U R E 1**

FIGURE 1A

1 M P K T R R R P R R S Q R K R P P T P W P [T S] Q G 25  
M1

26 L D R V [F F S] D T [Q S T] C L [E T] V Y K A T G A [P S] 50  
M2 M3 M4 M5

51 L G D [Y] V R P [A Y] I V T [P Y] W P P V [Q S I] R S P G 75  
M6 M7 M8 M9 M10

75 T [P S] M D A [L S] A Q L [Y S S] L S L D [S P P] S P P 99  
M11 M12 M13 M14 M15 M16

100 [R E] P L R P [S R S] L P R [Q S] L I Q P P T F H P P [S S] 125  
M17 M18 M19 M20

126 R P C A N T P [P S] E M D T W N P P L G [S T S] Q P C 150  
M21 M22

151 L F Q T P D [S G] P K T C T [P S G E] A P L S A C T 174  
M23 M24 M25 M26

175 [S T S] F P P [P S P] G [P S] C P T 189  
M27 M28 M29

FIGURE 2A




FIGURE 2B




FIGURE 2C




FIGURE 2D

A B C D E F G H I




FIGURE 3

Mutant No.	Target sequence	Amino acid position No.	Mutant sequence
1	Thr-Ser	22-23	Asp-Leu
2	Phe-Phe-Ser	30-31-32	Leu-Asp-Leu
3	Gln-Ser	35-36	Asp-Leu
4	Glu-Thr	40-41	Asp-Leu
5	Pro-Ser	49-50	Asp-Leu
6	Tyr	54	Leu
7	Ala-Tyr	58-59	Asp-Leu
8	Pro-Tyr	63-64	Asp-Leu
9	Gln-Ser	69-70	Asp-Leu
10	Arg-Ser	72-73	Asp-Leu
11	Pro-Ser	77-78	Asp-Leu
12	Leu-Ser	82-83	Asp-Leu
13	Tyr-Ser-Ser	87, 88, 89	Leu-Asp-Leu
14	Leu-Ser	90-91	Asp-Leu
15	Ser	94	Leu
16	Pro-Ser	96-97	Asp-Leu
17	Arg-Glu	100-101	Asp-Leu
18	Ser-Arg-Ser	106, 107, 108	Leu-Asp-Leu
19	Gln-Ser	112-113	Asp-Leu
20	Ser-Ser	124-125	Asp-Leu
21	Pro-Ser	133-134	Asp-Leu
22	Ser-Thr-Ser	145, 146, 147	Gly-Asp-Leu
23	Ser	157	Leu
24	Pro-Ser	164-165	Asp-Leu
25	Gly-Glu	166-167	Asp-Leu
26	Leu-Ser	170-171	Asp-Leu
27	Ser-Thr-Ser	175, 176, 177	Leu-Asp-Leu
28	Pro-Ser	181-182	Asp-Leu
29	Pro-Ser	185-186	Asp-Leu

## FIGURE 4

#1:

CA·ACA·CCA·TGG·CCA·GAT·CTC·CAG·GGT·TTG·GAC

*Ry II*

#2:

TG·GAC·AGA·GTC·TTA·GAT·CTG·GAT·ACC·CAG·TCT

#3: TC·TTT·TCG·GAT·ACA·GAT·CTT·ACG·TGT·TGT·GAG

#4: AG·TCT·ACG·TGT·TTA·GAT·CTT·GTG·TAC·AAG·GCG

#5: AG·GCG·ACT·GGT·GCA·GAT·CTT·CTG·GGG·GAG·TAT

#6: CC·CCA·TCT·CTG·GGA·GAT·CTT·GTG·CGG·CCC·GCC

#7: AC·TAT·GTT·CGG·CCA·GAT·CTC·ATC·GTC·ACG·CCC

#8: CC·TAC·ATC·GTC·ACA·GAT·CTC·TGG·CCA·CCT·GTC

#9: AC·TGG·CCA·CCT·GTA·GAT·CTC·ATC·AGA·TCA·CCG

#10: CT·GTC·CAG·AGC·ATA·GAT·CTA·CCT·GGG·ACC·CCA

#11: GA·TCA·CCT·GGG·ACA·GAT·CTG·ATG·GAC·GCG·TTA

#12: CA·TCG·ATG·GAC·GCAGAT·CTG·GCT·CAG·CTC·TAC

#13: TCG·GCT·CAG·CTC·TTAGAT·CTC·TTA·TCG·CTC·GA

#14: AG·CTC·TAC·AGT·TCAGAT·CTC·CTC·GAC·TCC·CCT

\*15: GT·TCC·TTA·TCG·CTAGAT·CTC·CCT·CCT·TCC·CCA

\*16: CC·CTC·GAC·TCC·CCAGAT·CTC·CCA·CCC·AGA·GAA

#17: CT·CCT·TCC·CCA·CCAGAT·CTA·CCT·CTA·AGA·CCC

\*18: CCT·CTA·AGA·CCC·TTAGAT·CTC·TTA·CCC·CGC·CA

#19: GG·TCC·TTA·CCC·CGAGAT·CTA·CTC·ATA·CAA·CCC

#20: CA·TTC·CAC·CCT·CCAGAT·CTC·AGG·CCA·TGC·GCA

#21: GC·GCA·AAT·ACT·CCAGAT·CTC·GAA·ATG·GAT·ACA

\*22: CA·CCC·TTG·GGC·GGAGAT·CTC·CAA·CCU·TGT·CTT

\*23: TT·TTC·CAG·ACC·CCAGAT·CTC·GCC·CCC·AAA·ACC

#24: CG·AAA·ACC·TGT·ACAGAT·CTT·GGG·GAG·GCT·CCG

#25: CC·TGT·ACA·CCC·TCA·GAT·CTG·GCT·CCG·TTG·TCT

#26: CT·GGG·GAG·GCT·CCA·GAT·CTT·GCA·TGT·ACC·TCT

#27: CT·GCA·TGT·ACC·TTA·GAT·CTC·TTT·CCCCCCC·CCA

#28: CC·AGC·TTT·CCC·CCA·GAT·CTA·CCT·GGC·CCC·TCC

#29: CC·CCA·TCA·CCG·GGA·GAT·CTG·TGC·CCC·ACG·TGA

FIGURE 5

SP  
↓  
1 MAG RSG DSD E DLLKAV R LI KFL YQ S N PPPN 30  
M1 M2 M3 M4  
31 PEG TRQ A R R N R R R R W R E R Q R Q I H S I S E R I L 60  
M5 M6 M7  
61 S T Y L G R S A E P V P L Q L P P L E R L T L D C N E D C G 90  
M8 M9 M10  
91 T S G T Q G V G S P Q I L V E S P T V L E S G A K E 116  
M11 M12 M13 M14

FIGURE 5A

67                    78                    83                    86                    92                    116  
 S A E P V P L Q L P P L E R L T L D C N E D C G T S . . . . . . . . S C A K E

**Mutant**

pM15	D L							
pM16		D L						
pM17			D L					
pM18				D L				
pM19					D			
pM20						D L		
pM21							D L	
pM22								D L
pM23								E D L
pM24								K D L
pM25								E D L
pΔ9/19	D - - - - -							
pΔ18/19		D - -						
pΔ18/23			D - - - - -	L				
pΔ22/14				D - - - - -	- - - - -			L
pΔ23/14					E D - - - - -	- - - - -		L
pM27		A						
pM28			A					
pM29				A				
pM32					A			
pM33						N S		
pM34						V		
pM35				Q				
pM36				V				

**F I G U R E      6**

<sup>1</sup> atggcaggaaagacaggacgcgacgaaggacccatcctcaaggcagttagactcatcaaggttcttat  
**MET****Ala****Gly****Arg****Ser****Gly****Asp****Ser****Asp****Glu****Lys****Leu****Ile****Lys****Leu****Tyr**  
<sup>70</sup> caaagcaaccacccatcccgaggggacccgcacaggcccgaataagaagaagggtggaga  
**Gln****Ser****Asn****Pro****Pro****Asn****Pro****Glugly****Arg****Gln****Ala****Arg****Arg****Asn****Arg****Arg****Arg****Trp****Arg**

139 gagagacagacatccattcgatttagtgaacggatccattgacttatctggaggatctggaaactct  
GluArgGlnArgGlnIleHisSerIleSerGluArgIleLeuSerThrTyrLeuGlyArgSerAlaGlu  
208 cctgtcccttcagtcaccgcgttggagaqacttactttgttaacggaggatgtggaaactct  
ProValProLeuGlnLeuProProLeuGluArgLeuThrLeuAspCysAsnGluAspCysGlyThrSer

277 gggacgcagggttggaaacctcaatatttgtggatctccatacgtattggatcaggagctaaa  
GlyThrGlnGlySerProGlnIleUvaLGlusUserProThrValLeuGlusUserGlyAlaLys

346 gaatag  
Glu

## FIGURE 7

M1 CCT ATG GCA GGA GAT CTC GGA GAC AGC GA  
M2 GA AGA AGC GGA GAA GAT CTC GAA GAC CTC CTC  
M3 C CTC AAG GCA GTA GAT CTC ATC AAG TTT C  
M4 AG TTT CTC GAT CAA GAT CTC CCA CCT CCC A  
M5 G ACC CGA CAG GCA GAT CTG AAT AGA AGA AG  
M6 G GCC CGA AGG AAA GAT CTG TGG AGA GAG AGA C  
M7 G AGA CAG ATC CAT ATT GAA CGG ATC CTT AGC  
M8 GT GAA CGG ATC CTA GAT CTT TAT CTG GGA CC  
M9 TAT CTG GGA CGA GAT CTG GAG CCT GTG CC  
M10 CAG CTA CCA CCA GAT CTG AGA CTT ACT CTT  
M11 GAG GAT TGT GGA GAT CTT GGG ACG CAG GG  
M12 CAG GGG GTG GGA GAT CTT CAA ATA TTG GTC  
M13 CAA ATA TTG GTG GAA GAT CTT ACA GTA TTG GAG  
M14 CT ACA GTA TTG GAA GAT CTA GCT AAA GAA TAG

FIGURE 8




FIGURE 9




FIGURE 10





FIGURE 11A



EP 0 406 557 B1

F I G U R E 11B




FIGURE 12




FIGURE 12A




FIGURE 13

A

M21	M1	M22	M2	M23	M24	M25	M26	M3	M4	M27	
M P K	T R R R	P R R	S Q S K R	P P T P	W P T S Q G L D	R V	F F S D T Q S T C L E				40
41	M5			M6	M7	M8					80
T V Y K	A T G A P S L G D Y V R P A	Y	I V T P	Y W P P V Q S I	R S P G T P S M D						120
81	M9			M10	M11	M12	M13				
A L S A Q L	<u>Y S S L</u>	S L D S P P S P P R	E P L R P S R S I L P R Q S L I Q P P								
121	M14		M15		M16						160
H P P S S R P C A N T P P	<u>S E M D</u>	T W N P P	L G S T S Q P C L F Q T P	D S G I P K							
161 M17		M18									189
T C T P S G E A P L S A C T S T S F P P P	S P G P S C P T										

B




FIGURE 14





FIGURE 15



F I G U R E 16





FIGURE 17



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**